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Abstract 
 
The 4 Pillars™ Practice Transformation Program for Immunization is an evidence-based 
quality improvement program to improve immunization outcomes in primary care. The 
intervention strategies, implementation methods and the 4 Pillars™ of Convenience and Access, 
Patient Communication, Enhanced Vaccination Systems, and Motivation were informed by 
theoretical frameworks from the sciences of medicine, public health, systems and implementation 
and the social ecological model. The program was most-recently deployed in three different 
settings; a multi-center cluster-randomized clinical trial, a continuing medical education 
performance-in-practice module, and a quality improvement initiative in a regional community 
medicine health care organization. 
In clinical trials, the program demonstrated efficacy to improve increased uptake of 
seasonal influenza vaccine in children; meningococcal and Tdap vaccines and HPV initiation and 
completion in adolescents; seasonal influenza, pneumococcal, and pertussis vaccines in adults; and 
pneumococcal vaccines in older adults. Population-level cost-effectiveness models of the data 
report that the program was a good value with incremental cost-effectiveness ratios of $4937 
within American Board of Family Medicine physicians seeking continuing education credit and 
$31,700 as a clinical trial per quality adjusted life year gained. An analysis of the efficacy of the 
program as conducted in 63 practices of a primary care division of a large regional health 
v 
organization was inconclusive failing to replicate the results observed in clinical trials. Secular 
trends, data availability, and methodological limitations interfered with the fidelity of the 
intervention which led to sub-optimal results.  
Public Health Significance - System limitations in practice of health care were observed. 
Nearly all domains of medical quality improvement would benefit from substantial changes to the 
user experience at the point of care, health data systems interoperability, and the availability of 
consistent patient-level data for epidemiologic research and the development of simulation models 
of health systems and health behavior dynamics. Translating a complex intervention from a 
laboratory controlled clinical trial to an organization-directed quality improvement program is a 
significant challenge in public health. This process of scaling mirrors the barriers of influencing 
behavior in nested social ecological levels. Consequently, the 4 Pillars™ can provide guidance to 
improve efficacy of future public health programs.  
vi 
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Preface 
This manuscript covers nearly a decade of work to scale an interesting theoretical model 
of practice change in a physician’s office to a rigorous framework for health-system-based quality 
improvement programs targeting public health outcomes. It would not have been possible without 
the dedication of Drs. Zimmerman and Nowalk who first conceived of the 4 Pillars™ during their 
study of immunization practices in primary care. I am profoundly grateful for their mentorship and 
guidance throughout the many phases of this project. The technical jargon and aloof 
professionalism of their technical writings do not convey the depth of their altruism and humility. 
Their influence on public health will inevitably extend beyond their scientific discoveries to the 
professionals who are blessed to serve with them. Likewise, I am equally thankful to the faculty 
of the Graduate School of Public Health and my advisory committee who have offered empathy, 
encouragement and critique whenever necessary. Finally, I am most thankful for my wife who has 
a seemingly endless supply of patience and enthusiasm whenever my determination has waned. 
It would be impossible to acknowledge of all the individuals who made important 
contributions throughout this journey. There have been so many people who have given generously 
of their experience, time and resources with no expectations beyond the hope that they might make 
something better for someone else. My experience through every chapter of this epic has reinforced 
that the often-maligned institutions of government, healthcare and big pharma are actually staffed 
by some of the most caring, committed and compassionate professionals in the workforce. Our 
modern understanding of health, disease and treatment would not be possible without their tireless 
effort towards solving extraordinarily difficult problems. Now, more than ever, these entities will 
need to cooperate to translate individual health to population health. 
xiv 
Since before the discovery of farming, through the industrial revolution, and continuing 
into the information era, our species has demonstrated superior adaptability through technological 
innovation. As our global population continues to grow, new challenges are being revealed on an 
almost daily basis. If we are to have any hope of preventing apocalypse while working to colonize 
Mars, many new skills, techniques and philosophies will need to incubate in safe environments 
where they can be nurtured through intellectual germination. I am excited to be a part of this next 
cycle of agrarian evolution where ideas become the crops that nourish and enrich our civilization. 
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1.0 Immunization Quality Improvement in Primary Care Practices 
Despite major advances in immunization science with the licensure of effective vaccines, 
they are often underused. To a clinician, the patient sitting in the exam room suffering from a 
disease seems far more compelling than all of the unseen, averted cases prevented by excellent 
care. Perhaps it is part of a healer’s nature to focus on disease rather than on health. Health seems 
nebulous and precarious, while disease is concrete and measurable. Yet, one of the top ten 
achievements of modern medicine is immunization.(1) 
Immunization is an exemplar of successful public health programming. In one of the 
greatest cooperative achievements of humankind, smallpox was declared globally eradicated a 
mere 200 years after the initial discovery of variolation. Given that this was accomplished during 
the infancy of modern epidemiologic surveillance techniques, vaccine manufacturing processes, 
and before the age of rapid international travel, our modern challenges to routine vaccination seem 
trivial compared with those faced by early vaccination pioneers.(2) By learning from experience 
and systematically building on success, the eradication of smallpox was just the beginning of mass 
prevention of infectious diseases. With the eradication of polio in sight, our global community has 
demonstrated that even the most obstinate barriers to immunization can be overcome.(3) 
While global eradication of a virulent pathogen is a noble objective, the routine control of 
the cadre of less spectacular illnesses has an even greater ability to extend life. Between 1900 and 
1997, average life expectance in the United States was extended by 29.2 years, largely due to the 
reduction of mortality from infectious diseases in children under 5 years of age.(4). Even mediocre 
success in controlling influenza (the most devious of vaccine preventable diseases) has resulted in 
the estimated prevention of up to 6.6 million cases and 79,000 hospitalizations per year in the 
2 
United States between 2005 and 2013.(5) Despite these obvious public health triumphs, the US 
vaccination program is still far from perfect. 
Vaccination opportunities still exist and with varying degrees of severity. In Healthy 
People 2020(6), the CDC reports vaccination coverage rates are below target for: ≥4 doses of 
diphtheria, tetanus, and acellular pertussis vaccine (DTaP), the full series of Haemophilus 
influenzae type b (Hib) vaccine, hepatitis B (HepB) birth dose, ≥4 doses pneumococcal conjugate 
vaccine (PCV), ≥2 doses of Hepatitis A, the full series of rotavirus vaccine, and the combined 
vaccine series; (7) Human Papillomavirus (HPV) vaccine in adolescents; (8) and seasonal 
influenza vaccination. (5, 9) However, a more troubling observation than sub-par vaccine-specific 
rates is the systematically low rates of vaccination among entire demographics, particularly adults 
(10) and the underprivileged and vulnerable. (7) Improving universal vaccination coverage in the 
United States will certainly take resources, determination and effort. However, the example of 
global smallpox eradication, led by D.A. Henderson, demonstrates what is possible when 
unwavering conviction and steadfast tenacity are applied to the obstacles to improving vaccination 
rates.(11)  
1.1 Theoretical Models Relevant to the US Immunization System 
1.1.1  Social Context of Immunization Behavior 
In comparison to other health behaviors, the behavior of vaccination is simple. For some 
vaccine preventable diseases (VPD), even a single inoculation is sufficient to provide lifelong 
protection. As compared to weight loss, smoking cessation or the maintenance of healthy levels of 
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physical activity, the binary decision associated with vaccination should be less difficult than 
avoiding the onslaught of temptations that threaten the daily confirmation of healthy lifestyle 
decisions. Therefore, it seems logical to focus considerable effort at the individual level to have 
patients say, “yes” to vaccination at the point of care. However, the application of individual-level 
theories, while important, is unlikely to drive results at a population level. 
1.1.2  Immunization Services at a Societal Level 
The social ecological model(12), as depicted in Figure 1 (13), defines a nested hierarchy 
of social-psychological influences that account for variances in behavior. For example, in an 
analysis of the uptake of the 2009 H1N1 influenza vaccine among United States adults, Kumar, 
Quinn, et al. (14) found that each social ecological level was a significant predictor of both 
intention and uptake. The variances in vaccine uptake were the individual level (53%), the 
interpersonal level (47%), the organizational level (34%), the community level (8%) and the public 
policy level (8%). In combination, all levels explained 65% of the variance in uptake which 
suggests that a systemic approach could achieve more than interventions targeting any single level.  
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Figure 1 Socio-ecological model 
Leveraging the multiplicative effects that come from multi-systems interventions is critical 
to maximizing the effectiveness of vaccination interventions. The results presented above, quantify 
the influence of each of the levels of the social ecological model. While 65% sounds like a high 
number, it actually means that the model can account for most of the reasons why participants did, 
or did not, receive the vaccine. What it does not report, however, is how many people did receive 
the vaccine. That figure is much less encouraging. The US Centers for Disease Control and 
Prevention (CDC) estimated that only 20.1% of US adults were vaccinated with the 2009 H1N1 
influenza vaccine.(15) The 2009 H1N1 influenza pandemic is a frightening example of how far 
our public health system needs to advance to truly protect the population. If the 2009 pandemic 
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had been as virulent as the 1918 Spanish flu pandemic, a meager 20.1% coverage rate would have 
left millions of adults susceptible to a potentially deadly infection. 
If the social ecological model can account for most of the variance in immunization 
behavior, then why are coverage levels lower than desired? First, the application of multi-level 
models, like the example above is an avant-garde approach to conceptualizing health outcomes. 
As evidenced by the corpus of immunization publication, a great deal of scientific effort has 
focused on the individual predictors of health behavior with decreasingly less rigorous scrutiny 
applied to the ascending intermediate social levels. The analysis from Kumar, Quinn, et al.(14) 
presented above mirrors this supposition. While it is possible that the ascending social strata are 
less predictive of individual behavior, it is also possible that the current extra-personal 
interventions are too feeble to produce a substantial effect. For example, our national vaccination 
plan includes some specific interventions in public policy, including publicly subsidized 
vaccinations and compulsory vaccination programs, but by largely excluding adults, those policies 
have been inconsistently applied to the population. Additionally, immunization interventions at 
the interpersonal level (like social marketing(16)), the organizational level (like employer 
mandated vaccination(17)), and at the community level (like pharmacist administration of 
vaccine(18)) are all fairly new efforts. For these reasons, future analyses of health behavior may 
find that the broader levels of the social ecological hierarchy will contribute an increasing greater 
proportion of influence. 
In addition to the novelty of the simultaneous application of multi-level interventions, the 
second reason for sub-optimal outcomes is that the interdependencies among levels is not well 
understood. Acknowledging that immunization interventions need to target multiple levels of the 
social ecological hierarchy is good, intervening at multiple levels simultaneously is better, but still 
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difficult. To coordinate maximum impact on immunization rates, the entire US society (and, 
arguably, the global society) must be viewed as a complex dynamic system. The simplistic diagram 
of social ecological levels discretely nested like Russian dolls one inside another, ignores the 
tangled network of interdependencies woven within, between and among all of the levels of social 
organization.(19) 
1.1.3  The Social Determinants of Health as a Framework for Immunization Services 
The Commission on Social Determinants of Health was established in 2005 by the World 
Health Organization (WHO). This commission was charged with building a model of the social 
inputs to individual health. The resulting conceptual framework, the social determinants of health 
(SDH)(20), pictured in Figure 2, overcomes the limitations of the social ecological model by 
describing health as the result of a multi-level social structure that acts as a complex adaptive 
system. This framework is useful in planning and evaluating intervention strategies as potential 
leverage points can be examined within the system dynamics. This contextualization allows for 
the identification of unintended consequences resulting from non-obvious interactions among 
system variables.  
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Figure 2 Conceptual framework of the social determinants of health 
Similar to the social ecological model, the SDH places the individual within a mosaic of 
social institutions. Unlike the social ecological model, the SDH provides relationships among all 
of the components of the social hierarchy through explicit causal pathways. According to this 
framework, individual health is the product of the structural determinants of the society which 
produce intermediary determinants that feed back to the structural level in a cycle. The structural 
determinants are: 1) the socioeconomic and political context, including laws and policies, and 
cultural and societal values, and 2) the individual’s socioeconomic position, which is the product 
of social class factors including education, occupation and income. This structural context defines 
the boundaries of the health environment available to member of the society. An individual’s 
health state is further constrained by the additional influence of the intermediary determinants: 
material circumstances, behaviors and biological factors, psychosocial factors, and the health 
system as moderated by social cohesion and social capital. Finally, the resultant health states of 
8 
the members of the population influence the structural determinants for all of the society.(20) To 
clarify the operation of this framework consider US seasonal influenza policy. 
At the structural level, influenza policy is established by valuing the potential economic 
and social costs of various policy alternatives, weighed against the potential economic and social 
benefits of those alternatives. An extreme example might be the comparison between the policies 
of optional seasonal influenza vaccination vs. compulsory vaccination for everyone in the 
population. An analysis of these alternatives might find that compulsory vaccination could prevent 
the most cases of disease, but that the cost of policing universal coverage and the restrictions on 
individual liberty outweigh the expected health benefits. If, however, the political context was 
colored by a recent pandemic resulting in mass casualties, the expected benefits might supersede 
the costs of enforcement and the reduction in civil liberties. In addition to explicit policy directives, 
the socioeconomic context includes other seemingly unrelated factors. Structural elements such 
as, urban design, availability of mass transportation, funding for local health departments, school 
class sizes, and more can all play a role in the epidemiology of seasonal outbreaks. Thus, the 
decisions made at a societal level can exert additional influences on population health. This effect 
is translated to individuals though socioeconomic position. 
Those with advantageous socioeconomic positions receive greater benefit, or suffer less, 
from coincidental structural influences. Suppose that a policy of compulsory vaccination for 
children and optional vaccination for adults were to be adopted. An individual’s likelihood of being 
vaccinated would be a function of their socioeconomic position. An unintended consequence of 
this policy manifesting in socioeconomic position, might be the allocation of the available vaccine 
stock to the more profitable insured market resulting in a disruption in supply to the VFC program. 
This would leave some of the most vulnerable children unprotected. In the adult population, a large 
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proportion of the more educated and higher earning citizens might opt out of vaccination due to 
misinformation and pseudo-scientific deception.  
Resolving an individual’s health state during a pandemic would occur by first solving for 
the structural effects given the individual’s socioeconomic position, then subtracting the effects of 
the intermediary determinants, adjusting for moderating effects from social capital and then adding 
effects from the health system. For example, an unvaccinated impoverished child would be likely 
to fare poorly. In addition to contracting the virus, his/her health might be further compromised by 
caustic environmental conditions more common in low-income housing, delayed or neglected 
medical care from overworked or absent parents, and compounded by the endemic levels of 
psychological stress associated with poverty. Contrariwise, a middle-class vaccine abstainer, 
might experience less severe outcomes as his/her illness may not be compounded by additional 
environmental and psychological stressors.  
Social capital and the health system provide feedback loops from the intermediary 
determinants to the structural determinants. Social capital moderates the effects of socioeconomic 
position, while the health system mediates effects in individual health. For the low-income child, 
a lack of social capital would offer no counterbalance to the negative socioeconomic effects, while 
the more affluent adult might be able to further reduce illness intensity by taking advantage of 
available social supports such as using a family member to help with childcare and cooking for the 
family.  
A final opportunity to adjust health occurs when the individual interfaces with the health 
system. As a result of these individual’s socioeconomic positions, it is likely that the child may 
never receive medical care or that it may be deferred until the symptoms become so severe that 
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they become an additional household stressor, while the middle-class adult might access care early 
enough to benefit from antivirals which prevent additional disruption to daily activities.  
At the end of this chain of events, the resulting health states of the impoverished child and 
the middle-class vaccine objector will feed back to the socioeconomic context for each individual 
and may establish a new socioeconomic position prior to the next medical crisis. The child who 
could not be vaccinated suffered a more intense illness as a result of socioeconomic position, the 
lack of social capital, and minimal mitigation by the health system, this child did not improve in 
socioeconomic standing and may have even fallen below the starting position. The flu-stricken 
adult experienced a reduction in the potential severity of the illness resulting from the absence of 
poverty-related stressors, available social capital, and early access to the health system. While this 
individual probably did not improve in socioeconomic standing during the illness, the reduced 
severity, likely prevented a drop in standing if, for example, he/she were to have lost a job due to 
illness. 
The final process in this system occurs when the aggregate experiences of all members of 
society inform policy, programming and cultural values. If the impoverished child scenario 
becomes too common or is widely publicized, it may lead to changes in structural level 
interventions for the disadvantaged. Likewise, the minimized consequences of illness for the 
vaccine abstainer, might lead others to believe that vaccination is unnecessary. If that erroneous 
belief were translated into structural inputs (e.g. abolishing compulsory childhood vaccinations) 
the entire society would suffer as more people contract VPD. 
Within the health system, primary care providers are a logical focal point for interventions 
targeting preventative treatments such as immunization. However, focusing health system 
interventions too narrowly on the manipulation of individual-level constructs like knowledge, 
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attitudes, and beliefs about immunization is insufficient to substantially improve vaccination rates. 
While the common models applied to patient-provider interventions, such as, the health belief 
model(21), protection motivation theory(22), and the theory of planed behavior(23) can be useful 
in developing decision aids or in framing educational messages,(24, 25) they are inadequate as a 
guiding framework to improve population outcomes at either the practice or regional levels 
because the health system is, itself, a complex system. 
1.1.4  Immunization Services as a Complex Adaptive System 
Like many other public health initiatives, the US immunization program, functions as a 
complex adaptive system. A complex adaptive system is a collection of entities that produce an 
outcome through dynamic, interrelated processes. Complexity occurs when the variability in the 
relationships among the elements in the system becomes important. Note that being complex is 
different from being complicated. A system can be complicated without being complex. 
Complicated systems are characterized by long chains of if-then operations. This logic can even 
branch out into many alternate pathways, but the final outcome can always be anticipated by a 
logical flow of predictable intermediate outcomes. A complex system also has predictable 
processes, but the outcome is dependent on how these processes interact with one another. In a 
complex system, causal pathways circle back to prior processes to create feedback loops.  
For example, vaccine manufacturers want to produce as much vaccine as is necessary to 
immunize the population without creating a surplus that expires. A complicated version of the 
system would proceed linearly. Epidemiologists would estimate the required monthly inventory 
and the manufacturer would produce some fraction of that inventory with every production run. 
Then clinicians would administer doses. In this system, oversupply or shortage is inevitable since 
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the supply chain has no awareness of the demand. Adding a feedback loop to the system, makes it 
adaptable to fluctuations in demand. Such a feedback loop might be a weekly inventory monitoring 
system where some number of doses is established as a reserve. If the reserve is full, production is 
halted. If the reserve is not full, production continues. If the reserve is ever emptied, production 
accelerates, and the reserve number is increased. If doses in the reserve ever expire, the reserve 
number is decreased. Now the system is taking feedback from one process and turning that into an 
input for another process, thus making the system adaptable. Because of this ability to modify one 
process in response to another, the system maintains stability even under inconsistent conditions. 
(26) 
The broader immunization system functions in a similar way, albeit with many more 
processes occurring at a larger scale. Consider the introduction of the HPV vaccine. Initially, 
demand for the vaccine and uptake were nil because a vaccine was not available. Once the vaccine 
was approved for use in the population, demand and uptake rose, however the vaccine was only 
licensed and recommended for females. Because the primary aim of the program was vaccinee 
protection from HPV-related cancers, marketing, education, and clinician training centered on the 
vaccination of pre-teen and teenage girls. When, the Advisory Committee on Immunization 
Practices (ACIP) recommended the routine immunization of 11 and 12-year-old girls against HPV, 
CDC added the licensed vaccine to the Vaccines for Children Program (VFC) which guarantees 
that low income and impoverished children have access to all recommended vaccines. This system 
should have demonstrated increasing levels of coverage among girls and decreasing prevalence of 
cervical cancers later in life. However, several important relationships in the system created 
unintended feedback loops that inhibited the rapid adoption that was initially predicted. 
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First, cost and convenience of the vaccine was a substantial barrier. Not all providers accept 
VFC and thus some could not access VFC vaccine.  Some providers did not stock HPV vaccine. 
Furthermore, the 3-dose series over six months is recommended at an age when children typically 
make only annual visits. Second, the selective recommendation fueled a public debate about the 
perceived risks of the possible sexual disinhibition of vaccinated children and concerns about 
vaccine safety arose.(27) In a complex adaptive system, stability can be a benefit if the observed 
outcome is desirable, however in this case, the observed outcome (low rates) was undesirable. 
Because the feedback loops in the system (high cost, a three-dose series, and perceived risks of 
vaccination) were stronger than the effects of clinician counseling, widespread uptake was 
limited.(28) Changing the outcome in a system like this will not happen without modifying the 
underlying system dynamics. No amount of provider education would prove sufficient to 
overcome the existing feedback loops.(29) 
Fortunately, policy makers, clinicians and scientists recognized the problems and altered 
the assumptions of the original population models. By including boys and young men in the 
vaccination effort, women would experience greater protection from HPV-related cancers. 
Vaccination became “routinized” and large education efforts to prevent cancer occurred in the lay 
and provider communities.  Also, in the face of low rates, the economic benefits of the reduction 
of other HPV-related disease, like genital warts, head and neck, anal, and penile cancers, further 
argued for an expansion of the ACIP HPV recommendations.(30) Subsequently the vaccine was 
licensed for boys and recommended by the ACIP for all adolescents. This expanded the VFC 
formulary to include males and coverage under the Affordable Care Act occurred. Also, the 
universal recommendation has likely diminished the strength of the effect of parental refusal. 
Though risk perception is still cited as a barrier, the shift in public policy may have softened 
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objections enough that clinicians are now able to overcome parental hesitancy. The result of 
increased access, enhanced publicity, and routinized provider recommendations is increasing 
levels of coverage.(31, 32)   
This example illustrates that an individual’s health is determined by factors well beyond 
that person’s locus of control. While it is tempting to believe that every person can autonomously 
choose his or her own state of health through rational decision-making, the truth is that all people 
are subject to unexpected tangential influences that serve to limit the breadth of options available 
at the individual level. 
1.1.5  Implementation Science 
Though useful in understanding the context of the immunization system, the theoretical 
overview presented above offers no practical mechanisms for the alteration of the system 
dynamics. Only by designing, implementing and evaluating controlled interventions, can the 
system be coaxed into change. Primary care is an especially useful intervention domain for 
immunization services. As the health system delegates responsible for coordination of care and 
preventative treatment, PCPs are ideally positioned to alter system dynamics at the intermediary 
level. As such, PCPs, their staff, and the patient-provider interaction have been the subject of 
substantial scientific inquiry. A by-product of this scrutiny has been the observation and 
description of the factors related to the installation, adoption and maintenance of intervention 
strategies. The following section discusses the process of integrating evidence-based innovations 
into clinical practice. 
The field of implementation science addresses the process of translating research into 
practice through change. Change occurs during implementation, or, the institutionalization of the 
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set of conditions and behaviors required to successfully execute an evidence-based practice. 
Implementation science is not a replacement for health behavior theory nor a substitute for 
effective health interventions, rather it is a unifying framework that describes the relationships 
among factors in the external environment, the characteristics of the organization, the 
characteristics of the innovation, and the process of deploying the innovation.(33) This systematic 
study of change reveals solutions and problems outside of the innovation’s clinical effectiveness 
that also contribute to an intervention’s success or failure.  
Surprisingly, this is a new field of research evolving from the methodical development of 
evidence-based practices and programs. Though researchers have become better at manipulating 
health outcomes in small samples of the health system, they have struggled to complete the next 
logical step which is to consistently replicate and scale these programs in the larger population. 
Thus, implementation science was born to bridge this chasm between research and practice.(34) 
As the study of translation progresses, clinicians adopting new innovations will begin to achieve 
closer results to those predicted in clinical trials.   
While implementation science can benefit the deployment of even simple innovations, it is 
most useful when the innovation targets a complex system with a complex intervention. 
Immunization is an ideal case for the application of the principles of implementation science. The 
scope of immunization covers every level of the social ecological hierarchy and has inputs and 
outputs in all levels of the social determinants of health. Moreover, most single-component 
interventions will fail to produce a significant change in immunization rates. Achieving 
measurable improvement requires, multi-component interventions for which the emerging field of 
implementation science offers guidance to minimize the risk of program rejection and to maximize 
the effectiveness of a successful system change.  
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1.1.5.1 Stages of evidence-based program implementation 
The successful implementation of a complex evidence-based program is a process that will 
pass through the four stages pictured in Figure 3 (35): 1) exploration, 2) installation, 3) initial 
implementation and 4) full implementation. Note that this timeline is lengthy. For ambitious 
projects, such as a new immunization improvement program (IIP), full implementation may take 
months or longer to achieve. Also note that the process may continue indefinitely. This is certainly 
true of immunization. New vaccines will be released, recommendations will change, and staff will 
turn over. These time-related characteristics should shape expectations of the project. The first step 
in in an IIP is to come to understand the implementation environment. This happens in the 
exploration stage. 
 
Figure 3 The stages of implementation  
Exploration 
As the name implies, exploration involves setting aside one’s own opinions and seeking to 
understand the implementation environment from the perspective of other stakeholders. The first 
task during the exploration stage is to understand what issues contribute to the problem and why 
they occur (assess needs). The second task is to review available interventions that have 
17 
demonstrated improvement to the target outcome in other similar environments (examine 
intervention components)1. And, the third task is to evaluate the capacity of the organization to 
support the necessary strategies (consider implementation drivers). With that information at hand, 
one will be able to select the right intervention or components from an assigned intervention 
(assess fit). I.e. will the proposed strategy solve the identified problems within the constraints of 
the organizational capacity? 
These tasks remain the same for implementations of any size. The methodology used to 
arrive at an assessment of fit may need to be scaled up or down accordingly. In a small practice, it 
may be practical to interview members of the staff informally over the course of a few workdays, 
while in a multi-site healthcare system one may need to collect data through questionnaires, 
interviews, participant observation sessions, focus groups, or even hire trained personnel to assist 
with assessment.  
Installation 
During the installation stage, the implementation team should prepare all of the individuals 
and resources necessary to perform the intervention. Installation is as much about achieving the 
social psychological milestone of buy-in, as it is about logistics. Advanced warning helps to 
smooth acceptance of the changes. If this stage is skipped, the success of the implementation will 
be jeopardized, or at least delayed, to remediate the oversight and to attempt to hastily acquire 
                                                 
1 Bertram, et. al (2014) categorize intervention components with further refinement as: (a) model definition; 
(b) theory bases supporting those elements and activities; (c) the model’s theory of change; (d) target population 
characteristics; and (e) alternative models. Discussion of these intervention components has been omitted in favor of 
presenting a more accessible approach to implementation of an existing evidence-based immunization intervention. 
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necessary resources and/or overcome nagging resentments from staff. The ultimate change in 
outcomes is dependent on the three interrelated and compensatory implementation drivers of 
competency, organizational systems and culture, and leadership, which will be more fully 
discussed in the following section.  
Initial Implementation 
After months, or even years, of planning and development, a new immunization 
improvement program is ready to be deployed. While it is theoretically possible that all of the 
preparation will result in a unilaterally adopted and flawlessly executed intervention, the more 
likely scenario is that the program will encounter unanticipated problems, unexpected obstacles 
and unpredictable behavior. The primary objectives during the initial implementation stage are 
resolving these problems, overcoming these obstacles, and managing these behaviors.  
Full Implementation 
Some interventions may never achieve full implementation while others may become 
institutionalized rapidly. The speed and degree of adoption is related to the complexity of the 
change and the fit between the program activities and the skills and resources available to support 
the implementation drivers. When an organization can meet a program’s requirements for staff 
competency, systems and resources, and leadership dynamics, full implementation will occur with 
greater fidelity to the prescribed activities then when there is a miss-match between requirements 
and skills(36). The initial implementation stage is the time to adjust one or both of these parameters 
until program fidelity can be achieved. 
Once the organization is reliably performing the specified activities, focus will shift to 
maintenance of the new processes and evaluation of outcomes. Full implementation is the time to 
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evaluate program outcomes at scale. If there is a large discrepancy between the expected and 
observed outcomes, one can attempt to achieve better program fidelity through the implementation 
drivers or begin a new exploration phase to choose an intervention with a better fit. Otherwise, the 
improved outcomes should be monitored for consistency through time.  
1.1.5.2 Implementation Drivers 
Implementation drivers are the most important determinants of implementation success. 
The three components of competency, leadership, and organizational environment presented in 
Figure 4 (35) all contribute equally to an intervention’s potential effectiveness. Competency 
drivers are largely influenced by human resources and staff performance management. 
Organization drivers reflect the translation of changes in external policies and conditions to 
internal business practices or treatment protocols. Lastly, leadership drivers, include the 
availability and characteristics of project leadership.(35) All of these drivers are addressed 
throughout all of the stages of implementation. In the exploration stage, the implementation team 
compares what is required by the intervention with what is available within the organization. In 
the installation stage, the systems and processes that support the program are deployed. During 
initial implementation, the program is tested, and the implementation drivers are adjusted. Finally, 
in full implementation, the organization executes the intervention activities with fidelity and 
continues to build on successes. 
20 
 
Figure 4  Implementation drivers 
The over-arching goal in aligning implementation drivers is to achieve program 
fidelity.(34) While there is considerable flexibility in how the program is installed and in what 
components are selected as an appropriate fit for the environment, the actual execution of the 
prescribed activities should remain as close to those that have demonstrated population-level 
effectiveness as possible.  
A fundamental challenge in any implementation is managing change. Disruption from the 
process of change can be minimized by using findings from the field of implementation science. 
Successful implementation of an evidence-based practice will progress through the four stages of 
exploration, installation, initial implementation, and full implementation. During each stage, 
competency drivers, leadership drivers and organizational environment drivers are aligned with 
program requirements and organizational capacity to insure implementation fidelity. Execution of 
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the program components with fidelity to the evidence-based model will result in a change in 
practice outcomes. 
1.2 Efforts to Overcome the Barriers to Immunization 
The Community Preventive Services Task Force (Task Force) is charged with 
systematically reviewing and synthesizing the results of peer-reviewed intervention studies across 
a spectrum of population health conditions. The Community Guide, available at 
http://www.thecommunityguide.org, contains the findings and recommendations reported by the 
Task Force and includes an extensive section on increasing appropriate immunization. Because 
the Task Force conducts rigorous evaluations that are peer-reviewed by stakeholders from 
research, policy, practice, and government agencies, including the CDC, The Community Guide 
is a trustworthy and comprehensive resource. (37) 
In the evaluation of interventions to increase universally recommended vaccinations, The 
Community Guide presents the findings from 22 recent systematic reviews and recommends 15 of 
the evaluated strategies. The Task Force suggests that additional research is necessary to issue an 
opinion on the remaining seven strategies and did not “recommend against” any of the reviewed 
strategies. (37) The review’s logic model groups interventions into the five categories: 1) 
interventions enhancing access to immunization services, 2) interventions to increase community 
demand for immunizations, 3) provider-based interventions, 4) interventions to promote seasonal 
influenza vaccinations among healthcare workers, and 5) interventions to promote seasonal 
influenza vaccinations among Non-Healthcare workers. (38, 39) 
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One strength of the Community Guide is its “stock and flow” perspective which assumes 
that increasing demand for immunization and/or increasing access to immunization will increase 
the number of patients seeking vaccination. When those patients engage with the health care 
system, provider-based interventions will increase the proportion of vaccinated individuals. This 
framework is logical from a population-based disease transmission perspective as it mirrors the 
common susceptible, infected, recovered (SIR) model that is very familiar to epidemiologists.(40)  
Another strength is that front-line immunization champions, would likely find the common 
themes in the recommendations of the Community Guide intuitive. First, simply increasing access 
to immunization is effective in multiple settings and across diverse populations. Reducing financial 
burdens, reducing opportunity costs, and offering more convenient locations for vaccination all 
contribute to increased uptake. Second, many people seem willing to be vaccinated when they are 
reminded, it is routine or required, or influential social factors are leveraged to encourage 
vaccination intention. Also, knowledge of vaccine status and vaccine education are necessary but 
insufficient to elicit vaccination intention. Third, practitioner-based interventions are sensitive to 
increased system efficiency and automation and achieve maximal effectiveness when implemented 
in combination with other strategies. Finally, clinicians respond to motivation.  
Limitations exist; a review of Vaccination illustrates that this framework has limited use 
from a patient-panel, clinician-centered perspective, since the organizational scheme used in the 
Community Guide blends the intention of the intervention (Enhancing access and increasing 
demand) with the locus of intervention (provider, system, or workplace). Additionally, many of 
the strategies involve socioecological levels outside of a clinician’s sphere of influence. Thus, 
practitioners who want to overcome barriers to immunization need a more action-oriented 
framework to conceptualize possible intervention strategies. Also, most provider-based 
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interventions target a single or small set of PCP-centered inputs. Consequently, the observed 
effects are minimal when the PCP is isolated from other components in the immunization system. 
Though implementing interventions in combination is recommended, when multiple strategies are 
incorporated into a single intervention, PCPs can quickly become overwhelmed with 
implementation complexity. Therefore, a successful PCP-centered immunization intervention 
requires the thoughtful combination of evidence-based strategies into a multi-faceted program that 
respects the limitations of the primary care team and incorporates the best-practices of 
implementation science. 
Table 1 Task Force Recommendations and Findings to Increase Appropriate Vaccination 
 
Recommended Insufficient Evidence 
Recommend 
Against 
Enhancing Access to Vaccination Services 
Home Visits to Increase Vaccination 
Rates X 
  
Reducing Client Out-of-Pocket Costs X   
Vaccination Programs in Schools and 
Organized Child Care Centers X 
  
Vaccination Programs in WIC Settings X   
Increasing Community Demand for Vaccinations 
Client or Family Incentive Rewards X   
Client Reminder and Recall Systems X   
Community-Based Interventions 
Implemented in Combination X 
  
Vaccination Requirements for Child Care, 
School and College Attendance X 
  
Client-Held Paper Immunization Records  X  
Clinic-Based Education when Used Alone  X  
Community-Wide Education when Used 
Alone 
 X  
Monetary Sanction Policies  X  
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Table 1 Continued 
Provider or System-Based Interventions 
Health Care System-Based Interventions 
Implemented in Combination X 
  
Immunization Information Systems X   
Provider Assessment and Feedback X   
Provider Reminders X   
Standing Orders X   
Provider Education when Used Alone  X  
Interventions to Promote Seasonal Influenza Vaccinations among Healthcare Workers 
Interventions with On-Site, Free, Actively 
Promoted Vaccinations X 
  
Interventions with Actively Promoted, 
Off-Site Vaccinations 
 X  
Interventions to Promote Seasonal Influenza Vaccinations among Non-Healthcare 
Workers 
Interventions with On-Site, Reduced Cost, 
Actively Promoted Vaccinations X 
  
Interventions with Actively Promoted, 
Off-Site Vaccinations 
 X  
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2.0 The 4 Pillars™ Practice Transformation Program 
Zimmerman and Nowalk (41) offer the 4 Pillars™ Practice Transformation Program for 
Immunization as a multi-component immunization improvement intervention targeting primary 
care providers. The program aggregates existing evidence-based strategies applicable to PCPs into 
the context of the clinical environment by defining a taxonomy of critical leverage points. These 
are presented as the 4 Pillars™, which are: 1.) convenience and access, 2.) patient communication, 
3.) enhanced vaccination systems, and 4.) motivation. Additionally, the process of implementation 
is supported with protocols and custom-created software designed to mitigate many of the threats 
to behavioral interventions by increasing fidelity. This hybrid approach, where the implementation 
of the intervention is supported as strongly as the intervention strategies themselves, has led to 
encouraging successes in health outcomes. (41-43) Clinical trials of the 4PPTP have shown 
increased uptake of seasonal influenza vaccine in children, (44-47) and seasonal influenza, 
pneumococcal, and pertussis vaccines in adults. (42, 48) Also, evaluation of the clinical 
implementation, supports the Community Guide recommendations for multi-faceted health care 
system-based interventions. (37, 49) 
2.1 Pillar 1: Convenience & Access 
Access to care is a strikingly complex barrier to immunization. Truly providing complete 
access to all patients is elusive and can be frustrating as barriers are removed only to reveal new 
hidden obstacles.(50) Similarly, some practitioners may overlook opportunities to increase access 
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to immunization by focusing on the societal level impediments rather than the myriad small ways 
they can make vaccines more widely available to their patients. 
Penchansky and Thomas (51) suggest that access to care has five dimensions that describe 
a patient’s “degree of fit” with the health system. Primary care providers can extend this taxonomy 
to describe a given patient’s degree of fit with their practice, their vaccination services, and even 
a specific vaccine.  
Availability is the value of the relationship between supply and demand. A primary care 
provider is available when a community has enough clinicians to offer services to the population. 
Influenza vaccine is available when a provider has enough stock to immunize all the patients who 
are eligible to receive it during the flu season.  
Accessibility is a measure of the perceived distance between the location of the patient and 
service. A clinic is accessible if it is within a reasonable commute from a patient given the available 
transportation. A vaccine is accessible if it is administered at the patient’s home or workplace.  
Accommodation describes the patient’s perception of feasibility to receive care. A 
schoolteacher may perceive a clinic as accommodating if s/he can schedule an appointment after 
school hours or on the weekend. A provider who offers no-wait, walk-in flu shots is showing 
accommodation for flu vaccination.  
Affordability measures the patient’s ability to pay for the services provided as well as their 
perceived value of the services and knowledge of payment options. A primary care provider is 
affordable if the patient can pay for routine and unexpected care without extraordinary financial 
burden. A vaccine administration is affordable if a patient is willing to sacrifice the time, money, 
and effort necessary to receive the vaccine as well as any research and paperwork necessary to 
receive reimbursement for out of pocket costs. 
27 
Acceptability relates an individual’s knowledge, attitudes, and beliefs about a resource to 
the actual characteristics of that resource. A PCP is more likely to be acceptable to a patient if the 
patient perceives the clinician as willing to listen. A vaccine is more likely to be acceptable to a 
patient if the clinician presents the benefits, common side effects and the uncommon risks.  
The preceding examples of access to primary care and access to immunization are only a 
start to the methods a practitioner might employ to increase access to vaccination services. 2.1.1  
lists evidence-based strategies from the 4PPTP that can be used to increase the convenience to and 
access of vaccination services.  
Offering accessible vaccination services is key to reducing social and healthcare inequities. 
(52) Providing equal access means solving problems that are subtler than a simple determination 
of insurance coverage. While expanding the population of insured individuals may be out of the 
scope of an individual physician, that physician can certainly manipulate many elements of 
availability, accessibility, accommodation, affordability, or acceptability to increase access to 
vaccination services.  
2.1.1  Pillar 1 - Convenience & Access Strategies 
• Use every patient visit type as an opportunity to vaccinate, including nursing, acute, 
chronic care, follow-up visits for visits for another vaccination. 
• Offer open access/walk-in vaccination during office hours. 
• Promote simultaneous vaccination (e.g., offer other vaccines at the time of 
influenza vaccination.) 
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• Hold express vaccination clinics outside normal office hours where only vaccines 
are offered, with streamlined flow systems for check-in, screening, and record 
keeping. 
• Create a dedicated vaccination station. 
• Extend the influenza vaccination season by vaccinating as soon as supplies arrive 
and continuing to vaccinate as long as flu is circulating in the community. 
2.2 Pillar 2: Patient Communication 
Patient refusal is one of the most obvious barriers to vaccination and is undoubtedly the 
most frequently blamed “reason” for sub-optimal vaccination rates. Refusal is a problem but 
occurs much less frequently than one might imagine. Leask and Kinnersley (53) estimate that less 
than 2% of parents in a sample of western countries are absolute refusers with the remaining 98% 
ranging from late or selective to unquestioning acceptor. While one should consider how to 
communicate with vaccine refusers, one should also refrain from allowing the vocal minority to 
become overly distracting. In actuality, the most important instances of patient communication 
occur well before the point of asking for consent to vaccinate. 
The ‘Communicate to vaccinate’ project developed a taxonomy of communication 
objectives identified in published immunization interventions.(54) The range of potential 
audiences and communication strategies resulting from the project underscores the importance of 
examining every patient engagement for opportunities to optimize communication. Though all of 
the communication purposes presented in Figure 5 (54) are potentially useful, primary care 
providers will likely use the objectives related to reminder and recall and patient education the 
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most frequently. Of those two aims, reminder and recall interventions are more effective in 
increasing uptake if no other strategies are enlisted while patient education requires the support of 
additional leverage points to achieve a noticeable increase in vaccine uptake.(37, 38)  
 
Figure 5 COMMVAC taxonomy purposes and definitions 
To many practitioners, patient education can become the default intervention strategy for 
every quality improvement program. This makes sense as clinicians are passionate about patients 
as individuals and want to achieve the most healthful outcome for every patient at every visit. 
While this is important, effective patient communication efforts must include strategies that act 
well outside of the exam room. Ideally, effective patient communication eliminates the need for 
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intensive education because the patient walks into a visit asking for a vaccine. Additionally, 
focusing communication efforts on short, routine interactions can reach the largest number of 
patients with the least amount of effort. 
Consider the time prior to a patient’s appointment in the context of the Transtheoretical 
Model(55) as illustrated in Figure 6. Prior to any external cues, all of the eligible and unvaccinated 
patients will exist in the Precontemplation stage. Some proportion of these people may 
spontaneously schedule appointments for vaccination in response to school or workplace 
requirements and some others in response to media or other mass communication initiatives. The 
remainder (especially adults) will need to be shepherded onto the schedule with a Remind or Recall 
program. This initial contact is a moment to create awareness of vaccination and to move patients 
from a Precontemplation stage into a Contemplation stage. Every subsequent encounter prior to 
the visit offers another opportunity to Inform or Educate patients with positive messages or 
reminders about vaccination. Once in the office, posters, fliers, and decision aids can help patients 
work through the Preparation stage or bring any precontemplators who ignored prior cues into the 
process. Rooming the patient and taking vital signs are opportune times to Enable Communication 
and to Facilitate Decision Making by checking vaccination status and exposing patients to more 
posters, fliers, and decision aids. If the practice has implemented standing order protocols for 
vaccination (see Pillar 3) all vaccines could be administered by the rooming medical assistant or 
nurse prior to the first contact with the clinician. Finally, during the clinician’s consultation, any 
remaining objections to vaccination can be addressed. By the end of the communication cycle, all 
patients will have been given every possible opportunity to overcome any personal reluctance to 
immunization and to act by accepting all overdue vaccines. 
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Figure 6 Patient communication opportunities prior to, and during appointment 
Communication with patients about immunization, however, is much more than carefully 
delivered monologues in the exam room. While skillfully responding to the concerns of vaccine 
hesitant patients is important, a much larger audience exists outside of the office walls. Using every 
engagement with patients as an opportunity to enable communication and to provide a small dose 
of education or information will deliver a sustained and consistent message that cannot be 
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duplicated in a single appointment. See 2.2.1 for a list of evidence-based patient communication 
strategies from the 4 Pillars™ Practice Transformation Program. 
2.2.1  Pillar 2 - Patient Communication Strategies 
• Enroll patients in electronic health portal. 
• Provide information about vaccine preventable diseases at the beginning of every 
visit. 
• Train staff to discuss vaccines during routine processes such as vital signs. 
• Discuss the serious nature of vaccine preventable diseases. 
• Promote 100% vaccination rates among staff to set a good example. 
• Use on-hold messages, poster, fliers, electronic message board, website posting, 
and social media to promote vaccination. 
• Reach out by email, phone, text, mail, health portal etc. to recommend vaccines that 
are due and about arrival of influenza vaccine supplies. 
2.3 Pillar 3:  Enhanced Vaccination Systems 
For decades, epidemiologists, clinicians, policymakers, and manufacturers have continued 
to extend an increasingly robust immunization infrastructure closer and closer to each member of 
the population. As always, the familiar dyad of the physician and patient are left at the end of that 
complex chain to overcome any barriers. As a public health program, immunization is both blessed 
and cursed by a dependence on standardization and automation. Immunizing the entire human race 
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can only be achieved through standardization, routinization, and complex systems support. This is 
a benefit to the program of immunization because ambiguity in any part of the process is 
systematically replaced with well documented policies and procedures. This prescriptive 
information can then be transformed into algorithms, programs, and industrial processes that 
eliminate a great deal of human intervention. Unfortunately, this dependence on automation and 
standardization can introduce new problems. Errors can impact enormous numbers of people and 
conversely, improvements can take substantial time to deploy. 
There are three major systems that have demonstrated positive influences on vaccination 
outcomes: 1) immunization information systems, 2) provider reminders, and 3) standing orders for 
vaccination. Additionally, clinicians should also consider how their unique office systems can be 
enhanced to support vaccination services. 
2.3.1  Immunization information systems 
An immunization information system (IIS) is a centralized repository of personally 
identifiable vaccination information for individual members of the served population. Nearly all 
US states now operate an active IIS however the features and functionality of each system is 
variable. During this period of transition to centralized vaccination registries, the Immunization 
Information Systems Support Branch, CDC - National Center for Immunization and Respiratory 
Diseases (NCIRD), directs expectations through an incrementally more complex set of functional 
standards for IIS. These standards were introduced in 2001, incremented in 2013 and will be 
evaluated again in 2017.(56) The technical standards support the programmatic goals of CDC-
funded Immunization programs and state vaccine registries listed in 2.3.2 . 
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2.3.2  Programmatic goals of CDC-funded Immunization programs (56) 
• Support the delivery of clinical immunization services at the point of immunization 
administration, regardless of setting. 
• Support the activities and requirements for publicly purchased vaccine, including 
the Vaccines for Children (VFC) and state purchase programs. 
• Maintain data quality (accurate, complete, timely data) on all immunization and 
demographic information in the IIS. 
• Preserve the integrity, security, availability and privacy of all personally 
identifiable health and demographic data in the IIS. 
• Provide immunization information to all authorized stakeholders. 
• Promote vaccine safety in public and private provider settings 
In practice, this registry system will overcome the frustrating and all too common barrier 
of accurate assessment of vaccination status. When fully implemented, an IIS will 
programmatically record detailed information for all vaccine administrations and report relevant 
data to authorized requestors on demand. This simple concept will enable automated information 
sharing among vaccine service providers, public health services, consumers, and possibly other 
participants in the national immunization program.(57) Despite the obvious benefits to be gained 
from a fully implemented IIS and conceptual simplicity, national deployment has been slow. 
Offering access to sensitive health information to such a breadth of stakeholders has a monumental 
list of challenges and threats and has necessitated a strategy of slow and deliberate incremental 
advancement. 
Unlike some other system enhancements, clinicians will likely have minimal involvement 
in the continued institutionalization of IIS but will reap ever increasing rewards from background 
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improvements to the infrastructure. The most important action item for providers is cooperation 
with any manual processes required to interface with the system, especially when accuracy can be 
compromised. Manually entering vaccination data into multiple databases, for example, may seem 
burdensome, but activities like this help every other stakeholder in the system to offer better 
services to patients. Ultimately, these chores will be replaced by the robust automation of the 
transfer of data between the EMR and the IIS. See 2.3.5 for some common strategies to maximally 
leverage IIS.  
2.3.3  Provider Reminder Systems 
Provider reminder systems notify clinicians that a vaccine should be administered to a 
specific patient at the point of care. The mechanism of this notification is less important than its 
existence and can take whatever form fits within the patient workflow. This strategy is effective 
for any vaccine and for any age patient and in nearly all clinical settings.(37) Reminders can be 
informally implemented as a note on a chart or formally implemented as programmatic 
notifications in the EMR (a.k.a., best practice alerts). (58, 59) The most important considerations 
are that the provider responsible for vaccination takes notice of the reminder during the patient 
encounter, and that the reminder is accurate. 
The mechanism of action for provider notifications has not been well studied.(60) 
However, there are numerous reports in the medical informatics literature of implementation 
details in EMR systems that may have an impact on outcomes. Additionally, there are some 
unintended consequences of the success of clinical decision supports like provider reminder 
systems. “Alert fatigue,” and cognitive overload are familiar concepts to most clinicians who work 
with an EMR.(61) The following elements are key elements of provider reminders: 
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What is displayed in the content of the reminder. 
How the reminder is presented to the clinician. This may include the use of consistent 
colors, visual cues, and terminology as well as the required level of interruption to the patient care 
workflow 
Where the reminder is presented in the salience hierarchy. For example, as a dialog box 
alert that appears immediately upon opening a patient record or as a footnote that is visible only 
after navigating deeply into the record. 
When the reminder is presented in the patient care workflow. (62)  
Because of the variability in office systems, primary care practices will need to implement 
provider reminders in whatever form makes the most sense within the business, operational 
structure and patient care workflow. Some organizations will be able to simply turn on 
functionality provided by an EMR vendor, some will need to define and enable custom prompts, 
while others will need to rely on the creativity of staff to create manual prompts outside of the 
EMR. Every implementation will have unique shortcomings, but reminders of nearly any 
description are better than missing an opportunity to vaccinate. 
2.3.4  Standing Orders for Vaccination 
Standing orders protocols for vaccination (SOP) allow authorized health care staff to assess 
vaccination status and administer vaccines without an examination or specific order from a 
physician at the time of the administration. Standing orders are established by clearly defining a 
protocol for vaccine status assessment and vaccine administration. The SOP can range from broad, 
including many vaccines and many patent sets, or narrow including a single vaccine and a single 
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patient set. This protocol is then approved by the appropriate personnel responsible for patient care 
and disseminated through training to all relevant clinical staff.  
Standing orders for vaccination can be one of the more difficult to implement provider-
based immunization interventions. However, the rewards in efficiency, increased vaccinations, and 
prevented cases of disease are well worth the effort, especially in the adult population.(63, 64) 
Both the Task Force on Community Preventive Services (65) and the ACIP recommend the use of 
SOPs in many contexts.(66) In fact, the positive impact of SOPs can hardly be understated. Among 
a sample of elderly inpatient hospital stays, the use of SOPs increased the identification of 
pneumococcal vaccination opportunities from 8.6% to 59.1%.(67) In a randomized trial of 3777 
hospitalized patients comparing SOPs to physician reminders, SOPs resulted in a 42% influenza 
vaccination rate vs. 30% from provider reminders, and a 51% pneumococcal vaccination rate vs. 
31% from provider reminders.(68) In a university-based practice, a retrospective analysis of 
patient visits over four years showed that the physicians who used SOPs achieved an influenza 
vaccination rate of nearly double those who did not use SOPs (63% vs. 38%).(69) Similarly, an 
implementation in an urban family medicine center resulted in a 1.4 fold increase in influenza 
vaccinations.(70) Clearly, all primary care clinicians should strongly consider adopting standing 
orders for vaccination. 
Standing orders are regulated by state law.(71) Since standing orders can be used in many 
healthcare settings such as hospitals, clinics, medical offices, and long-term care facilities, and can 
cover many provider roles such as, nurses, pharmacists, and medical assistants, describing specific 
regulatory details is difficult. Despite the inherent regulatory complexity, standing orders are a 
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well-known health care process with clear guidelines and prolific documentation.(66) Therefore, 
development and implementation of SOPs need not be stymied by excessive legal caution.2 
Unquestionably, implementing standing orders can be a challenge in some environments, 
but the healthcare benefits far outweigh the organizational effort. There are many excellent 
resources available from the CDC and other reputable partner organizations to help healthcare 
organizations and primary care providers plan and establish SOPs. A particularly useful library is 
maintained by the Immunization Action Coalition (IAC) at http://www.immunize.org/standing-
orders. 
Primary care providers must assess the office environment holistically to maximize the 
effectiveness of immunization systems, provider reminder systems, and standing orders for 
vaccination. See 2.3.5 for some common ways to enhance primary care office systems for 
immunization. These deep level alterations in routines, habits, and procedures will ultimately take 
less effort and result in much larger effects than from any campaign-oriented initiative. 
2.3.5  Pillar 3 - Enhanced Vaccination System Strategies 
• Ensure sufficient vaccine inventory to handle increased immunizations. 
• Assess vaccination eligibility for every patient encounter by a systematic 
mechanism: (1) review of EMR prompts, (2) vaccination as a vital sign, and/or (3) 
create huddle report at beginning of session of unvaccinated patients. 
                                                 
22 The George Washington University Center for Health Services Research and Policy, School of Public 
Health and Health Services provides a wealth of information regarding the governance of immunizations. Interested 
readers can access materials at http://publichealth.gwu.edu/departments/healthpolicy/immunization/ 
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• Review accurate EMR vaccination record keeping. 
• Update EMR with vaccinations as they are administered. 
• Update EMR with vaccinations given elsewhere. 
• Assess immunizations as part of vital signs. 
• Establish standing order protocols for nursing and other patient care staff to 
vaccinate without an individual physician order.  
• Develop systematic process for vaccinating every person with a vaccination need, 
such as standing orders or pending/queuing an order in the electronic health record. 
2.4 Pillar 4: Motivation 
The fourth pillar of the 4PPTP is Motivation of the clinical team. Making changes to 
established workflows and to office systems is not easy. A common objection to any quality 
improvement program is some variation on the lack of time and resources. From this perspective 
of resource scarcity, the very thought of conducting a deep, multi-system, multi-component 
intervention is almost farcical. Yet if change in outcomes is expected, then some change must 
occur. Faced with this reality many clinicians fall to the default intervention; education. The 
assumption is natural. One assumes that if he or she knows more, or can teach patients more, then 
positive results will follow. Unfortunately, in the domain of immunization, education is necessary, 
but not sufficient, to achieve measurable changes in vaccination rates. The kinds of changes that 
are required stress leverage points at every level of the healthcare organization and beyond. 
Immunization interventions are complex, multi-faceted, and involve many stakeholders. All 
seasoned clinicians will likely admit to having participated in at least one spectacular failure of a 
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complex intervention during his/her career; one that never got off the ground or if it did take flight, 
crashed into a wall of obstinate habits, stoic willfulness, or entrenched bureaucracy. Motivation is 
the dynamic that pushes individuals to move past these barriers. 
An observant reader may have already noted that the majority of strategies to overcome 
immunization barriers are really designed, though automation and habituation, to overcome our 
shortcomings as human beings. It is laughably ironic that engineering around human fallibility is, 
itself, subject to yet another level of human interference. Even the most carefully orchestrated and 
flawlessly planned quality improvement program can be hamstrung at the human/plan interface. 
But there is more to this story than fatalistic pessimism. How does one achieve change if it is so 
hard to do? How is it that some of the most haphazard and impromptu programs can succeed? Why 
do some practices consistently immunize the majority of their patients under the same 
organizational constraints? The answer, of course, is motivation. (72, 73) 
The Community Guide recommends assessing vaccine providers’ performance and 
offering feedback.(37) Though there is considerable evidence that feedback on past vaccination 
performance tends to increase future performance, the active mechanisms are relatively 
unexplored. The exact nature of an “audit” and of “feedback” is highly variable. For example, in 
the literature reviewed by the Community Preventive Task Force, an audit may be conducted as 
infrequently as every five years or as often as weekly. Similarly, feedback may be a list of 
unvaccinated patients, provider education, or even financial incentives tied to vaccination rates. 
Also, few studies examine audit and feedback in isolation. Many reports include co-occurring 
interventions or are confounded by secular trends. More research will be necessary to isolate and 
test different methodologies and causal pathways.(74)  
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Organizational motivation is a potential mediator in the effectiveness of audit and feedback 
strategies. Immunization interventions are complex and often involve individuals and business 
units who do not have close working relationships. Special care should be taken to engage all 
stakeholders in appropriate planning and preparation to secure institutional buy-in of the program. 
Failure to do so, may result in insufficient institutional motivation or even overt sabotage that will 
derail the project. (75) Applying the principles of implementation science can help to guard against 
these risks. The planning, deployment, and implementation of the program should be considered 
as carefully as each of the program activities. 
Immunization programs are dependent on team participation. If clinicians improve 
individual performance with audits and feedback, it stands to reason that teams will improve group 
performance with the same. The 4PPTP recommends the nomination of an immunization 
champion (IC) to serve as a team motivator.(48) This individual should be respected by the staff 
as a leader and be able to guide staff through system changes. (49)  The IC should also have strong 
interpersonal skills and enjoy frequent communication. The ideal IC finds win-win solutions to 
conflicts and demonstrates tenacity in overcoming roadblocks. Finally, the IC should be committed 
to the quality improvement goal and be nominated as the IC through purposeful consideration and 
not simply by default. 
Section 2.4.1 lists evidence-based strategies that the IC can employ to provide feedback to 
the team. In generating motivation, the quality of the audit is less important than the quality of the 
feedback. Obviously, audit results must be truthful, but absolute precision is unnecessary. ICs 
should use the data at hand to develop the best possible description of the practice’s baseline 
vaccination rates, generate reasonable but challenging targets and then start implementing 
strategies to try to improve rates. Someday all practices using an EMR will be able to summon an 
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accurate population-based report of real-time vaccination rates. Until that day arrives, using the 
readily available reports and measuring success as a change over baseline is sufficient. If no reports 
are available, simply tracking the number of doses administered per period, or manually auditing 
some small sample of charts is preferable to implementing a quality improvement program with 
no measures of effectiveness.  
Practice managers and organizational leadership can also provide a special kind of 
motivation. Operational policies like standing orders can be used to describe required job 
performance standards. By extension, employees can be compelled to fulfill these standards as a 
condition of employment. Though tempting, the formalization of best practices into job 
requirements may lead to more employee dissatisfaction than productivity.(76) 
2.4.1  Pillar 4 - Motivation Strategies 
• Create a chart to track progress. Set an improvement goal and regularly track 
progress (e.g., daily or weekly). Post the graph of progress in a prominent location 
and update it regularly. 
• Provide ongoing feedback to staff on vaccination progress at staff meetings or 
through other forms of communication. 
• Create a competitive challenge for the most vaccinations given among staff. 
• Provide rewards for successful results to create a fun-spirited environment. 
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2.5 The Evolution of the 4 Pillars™ Practice Transformation Program from Clinical Trials 
to Public Health Intervention 
The 4PPTP has been clinically tested across a multitude of experimental conditions. 
Results of these trials of the 4PPTP have shown increased uptake of seasonal influenza vaccine in 
children; (44-47) meningococcal and Tdap vaccines and HPV initiation and completion in 
adolescents; (77, 78) seasonal influenza, pneumococcal, and pertussis vaccines in adults; (42, 48, 
79) and pneumococcal vaccines in older adults. (80) Moreover, each application of the program 
offered opportunities to improve the delivery of the intervention methods culminating in the 
systematic and scalable current version of the program. 
The earliest version of the program was developed from an intervention to increase adult 
immunization rates among minority patients of inner-city health centers.(81) Investigators used a 
before-after design with four clinics and maintained a fifth site as a concurrent control. During the 
intervention period for each site, clinical staff were provided education on immunization in 
primary care and potential strategies for improvement sourced from systematic literature reviews. 
Each site selected strategies from a menu of options according to the staff’s perceived expectation 
of feasibility and effectiveness in their setting. Some examples of selected strategies were: 
• Adoption of standing orders for vaccination 
• Hanging of reminder posters 
• Looping video in waiting room 
• Mailed reminders for immunization including a coupon for a free vaccine 
• Walk-in influenza clinic 
• Recognition for prolific vaccinator 
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Among a random sample of patients aged 50 years old or older (n=568), the influenza 
vaccination rate increased from 27.1% to 48.9% (P<.001) and the PPV rate increased from 48.3% 
to 81.3% by the conclusion of the program in intervention sites. In the control site, changes in 
these rates were minimal and statistically insignificant. Logistic regression analyses controlling 
for age, race and sex, showed that rates for older adults (>65 years old) improved the most and 
that non-white individuals benefitted as much as white individuals. These findings suggested that 
the intervention was successful in the population and especially effective in the most vulnerable 
and underserved sub-populations. 
Having demonstrated success in older adults, Zimmerman et al. improved the program and 
tested its effectiveness to increase childhood influenza vaccination rates of primary care providers 
serving disadvantaged populations. (46) In this cluster randomized trial, twenty primary care 
practices were stratified by practice and patient characteristics and then randomized to intervention 
or control arms. Practices in the intervention arm received the intervention prior to the 2010-2011 
flu season. Practices in the control arm were informed that their intervention would begin in the 
following season.  
Preparation for this trial solidified the conceptual framework of the program. Insight gained 
during the previous effort led to two important changes in the program. First, the evidence-based 
strategies were organized into “The 4 Pillars” which emerged as: Pillar 1 – Convenient vaccination 
services; Pillar 2 - Notification of patients about the importance of immunization and the 
availability of vaccines; Pillar 3 - Enhanced office systems to facilitate immunization; Pillar 4 - 
Motivation through an office immunization champion. Second, the delivery of the intervention 
was orchestrated using Diffusion of Innovations theory. (82) These enhancements evolved from 
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careful observation of the behavior of clinicians and staff during program adoption and the need 
for standardized and repeatable intervention delivery methods. 
During the initial trial, investigators observed that the intervention protocol appeared to 
have been enhanced by spontaneously emerging system dynamics. In the published discussion of 
the results, the investigators propose that the collaborative engagement of the clinical teams may 
have contributed to the emergence of an unexpected catalyst contributing to the improvement of 
immunization rates. Though this tactic was employed to elicit multicultural perspectives in strategy 
selection, it appears to have also stimulated enhanced engagement and/or adoption of the program. 
Even a decade later, this self-actualizing methodology remains novel among the more focused and 
prescriptive models of quality improvement centered on clinician education. Similarly, in 
reviewing the proposed evidence-based strategies, clinicians recognized that their practices would 
have to alter more than just the clinical encounter to maximize opportunities to vaccinate their 
entire patient panel. Thus, the scope of strategies selected by the sites included a much broader 
context than the single interaction with an unimmunized patient. Rather, clinicians chose to focus 
change on structural and organizational leverage points that engage the entire treatment team as 
well as the unvaccinated in cooperative solutions beyond simple patient education.  
The awareness of these environmental contributors to program effectiveness required a 
new layer of complexity in the intervention. The 4 Pillars™ schema was developed to represent a 
taxonomy of strategies organized around influential processes in a larger perspective of preventive 
care. Each pillar captures a necessary-but-insufficient spectrum of processes that are associated 
with improved vaccination uptake. During implementation, clinicians were instructed to select 
strategies from each of the pillar domains so that the program remained manageable while still 
including all of the components necessary to produce measurable long-term results. 
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Likewise, the adoption of a theory-informed deployment strategy became necessary to 
strategically harness the amplifying effects of inter-clinician relationships. Diffusion of 
Innovations theory was a natural fit for this aim as it focuses on moving a large population toward 
behavior change through the early adoption of the desired behavior by a relatively small number 
of individuals. With reinforcement, more individuals adopt the behavior until a tipping point shifts 
environmental dynamics and the new norms become a more desirable state that further accelerating 
adoption. 
As predicted, the intervention significantly elevated influenza vaccination rates in the 
pediatric population. Among patients aged 9-18 years, overall improvement was 9.9 percentage 
points in the intervention group vs 4.2 percentage points in the control group. Additionally, when 
controlling for patient and practice characteristics, likelihood of vaccination increased for non-
white children in all age groups.(47) However, a more interesting finding appeared in a subsequent 
analysis of post-intervention maintenance. One year after completing the program, the intervention 
group maintained the gains achieved during the program and increased an additional 0.4 
percentage points (P > 0.05) without any further contact from the study team.(44) This finding 
suggested that the intervention achieved a change in the system which persisted beyond the 
termination of the program. 
Seeking to expand the reach, consistency and sustainability of the intervention, the research 
team initiated a larger multi-center trial. This cluster randomized trial was conducted in primary 
care practices in the Pittsburgh and Houston regions and targeted the improvement of specific 
vaccination rates in adolescents and adults. The expanded scope of required content, geographic 
distance and increased number of participant clinicians necessitated further enhancements to the 
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intervention protocol. With these enhancements, the program achieved significant reductions in 
missed opportunities to vaccinate adults leading to an improved vaccination rate. (83) 
The cost effectiveness and potential public health impact of the program have also been 
calculated from the research data and reported for select scenarios in the US adult population. 
These evaluations, discussed below, report that the program is cost-effective and would likely 
deliver value at the population-level. (84, 85) 
The 4PPTP is more than a theoretical framework for immunization improvement. The 
concepts discussed above have been integrated into a systematic and scalable intervention 
designed to be deployed with fidelity across a variety of primary care practices, organizations, and 
patient populations. This intervention methodology was concurrently developed with each 
increasingly complex clinical trial of the 4PPTP constructs. The most recent evaluations of the 
program, which will be discussed in subsequent chapters, measure effectiveness in real-world 
applications with teams who have adopted the program as a clinical care quality improvement 
effort rather than as participants in controlled laboratory conditions.  
2.6 Knowledge Gaps 
The 4 Pillars™ Practice Transformation Program for Immunization is a promising step 
forward for immunization interventions executed in primary care. Fidelity with evidence-based 
strategies is optimized, even in a complex multi-faceted program, by supporting the 
implementation team with protocols and software that comply with best practices identified by 
implementation scientists. This addition of another layer of theory, however, exposes new 
knowledge gaps that require further investigation. 
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Understanding which components of this intervention are most efficacious is a logical 
objective, but nearly impossible to gauge with traditional statistical methods. Because of the 
complexity of the program, interwoven relationships are difficult to isolate and quantify. A feature 
of the 4PPTP is the customizability of practice-specific strategies. To facilitate program fidelity, 
participating offices are allowed to choose from a menu of evidence-based strategies within each 
Pillar. This flexibility allows for the alignment of the most appropriate strategies given the 
available implementation drivers (see Figure 4) but presents analytic challenges as all teams may 
not necessarily choose the same strategies. Therefore, most statistical models will be hindered by 
the excessive permutations of demographic variables and treatment conditions. With infinite 
sample size, this limitation can be overcome. However, enrolling enough PCPs in a clinical trial 
to ensure model stability is resource prohibitive. Similarly, strategies are not necessarily 
independent of one another. Some are inherently correlated, and others exhibit complex 
relationships with other program strategies and contextual variables in the implementation 
environment. 
A second research and evaluation priority is the valuation of intervention strategies.  Cost-
effectiveness analysis, suggests that the 4 Pillars™ Program is cost-effective at the intervention 
level however, the relative cost-effectiveness of individual strategies has not been calculated. (86) 
Because of the broad range of effort required for individual strategies, understanding the return on 
investment for each activity would further help practices to align intervention drivers with strategy 
selections. Estimation of these values will be equally challenging as the actual effectiveness of 
each strategy is unknown. 
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3.0 The Expected Cost Effectiveness of the 4 Pillars™ Practice Transformation Program 
for Immunization in Adults 65 Years and Older 
3.1 Background 
The 4 Pillars™ Practice Transformation program for immunization (4PPTP) is an 
evidence-based immunization quality improvement intervention for primary care practices. The 
program was made available as an American Board of Family Medicine (ABFM) Performance in 
Practice Module (PPM). The cost effectiveness of its implementation is unknown. 
The 4PPTP for Immunization as a multi-component immunization improvement 
intervention targeting primary care providers. Grounded in the recommendations provided by the 
Community Preventive Task Force in the Community Guide (87), it acts at multiple leverage points 
in primary care by focusing on the treatment team rather than on the patient. Additionally, the 
program focuses on interventions that are applicable to all vaccines and all patients rather than 
focusing on a single vaccine or a single age group. This provides a generalizable framework for 
increasing vaccination compliance throughout the lifespan. The program guides PCPs and 
ancillary staff in the implementation of quality improvement strategies in the domains of: 1.) 
convenience and access; 2.) patient communication; 3.) enhanced vaccination systems; and 4.) 
motivation. Custom-created software, evidence-based protocols and prolific resources were 
included in the program to increase adoption, ease implementation and preserve program fidelity. 
(41-43)  
The program has undergone multiple iterations and has been evaluated in clinical trials in 
numerous populations. Results of these trials of the 4PPTP have shown increased uptake of 
50 
seasonal influenza vaccine in children; (44-47) meningococcal and Tdap vaccines and HPV 
initiation and completion in adolescents; (77, 78) seasonal influenza, pneumococcal, and pertussis 
vaccines in adults; (42, 48, 79) and pneumococcal vaccines in older adults. (80)  
The cost effectiveness and potential public health impact of the program have also been 
calculated from the research data and reported for select scenarios in the US adult population. In 
an analysis of the cost-effectiveness of the program in US adults under age 65, the 4PPTP was 
estimated to be an economical option at the societal level to increase Tdap and seasonal influenza 
vaccinations (ICER=$31,700 QALY gained). The model predicted that extrapolating the results 
observed in the clinical trials to the US adult population would result in the prevention of 4.2 
million cases, 87,489 hospitalizations and 5,680 deaths from influenza infection over a 10-year 
time horizon. If the cost per influenza case were to rise from the base case value of $846 to $2,099, 
the program would become cost saving at the societal level. (84) Among adults >65 years old, the 
program was even more cost-effective (ICER=$7,635/QALY gained) and could prevent 60,920 
cases of influenza, 2,031 cases of pertussis and 13,842 cases of pneumococcal illness over the 10-
year time horizon at the societal level. (85) 
The patient centered medical home initiative and realignment of the nation’s medical 
infrastructure through healthcare legislation are examples of the recent paradigm shift in medicine 
emphasizing prevention and effective coordination of care as key drivers of long-term health 
outcomes. Primary care physicians are uniquely positioned to advance this agenda by evaluating 
the health needs rather than treatment needs, of their patient panel. Mass vaccination is one of the 
most effective and important medical interventions available and ensuring every patient is 
appropriately immunized is reinforced by each of the primary care specialty boards. 
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All physicians certified by the American Board of Family Medicine (Diplomats) must 
provide evidence of competence, quality and continuing education to renew board accreditation. 
PPM are one avenue for Diplomats to demonstrate this.(88) The 4PPTP for Immunization was 
reviewed and accredited by the ABFM as a qualifying PPM. The program was listed online in the 
ABFM catalog of PPM offerings with a link to a private step-by-step version of the 4PPTP which 
was adapted to comply with ABFM PPM specifications. During the time that the 4PPTP was 
offered to ABFM Diplomats, approximately 30 physicians completed the program. Though the 
4PPTP intervention could have been used with any age group of adults, the disproportionately 
large and vulnerable cohort of US adults over 65 years had the greatest opportunity for measurable 
population health impact and was therefore, selected as the population for this analysis. 
Participating physicians who chose to focus on increasing vaccinations for older adults 
reported increased rates of vaccination for each of the available immunizations after completing 
the 4PPTP. Figure 9, shows the before and after rates. To evaluate whether an expanded program 
that achieved similar results at a national level would be economically viable, this analysis reports 
the potential cost effectiveness and public health impact of the 4PPTP at a societal level by 
modeling the costs and observed outcomes from the ABFM PPM in the United States population 
65 years old and older.  
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Figure 7 Pre/Post Immunization Rates by Practices Using the 4 Pillars™ Practice Transformation Program 
as ABFM PPM in 65+ year-old patients 
3.2 Methods 
To estimate the public health impact and cost-effectiveness of the 4PPTP for 
Immunization, a decision-tree cost-effectiveness model was constructed using TreeAge Pro 
Version: 2018 (64-bit), Build-Id: 18.1.1.0-v20180328. The model compared vaccination rates, 
health outcomes, and the costs associated with two hypothetical cohorts of US adults 65 years of 
age or older over 10-year time horizon whose primary care physicians were either a) exposed to 
the immunization intervention or b) provided standard clinical care. Intervention effects were 
generated by an ongoing ABFM PPM using the 4PPTP for immunization. The University of 
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Pittsburgh Institutional Review Board approved the analysis and data security plan 
(PRO17120018). 
3.2.1  Vaccines 
The ACIP recommends routine immunization against influenza, tetanus, diphtheria, 
pertussis, herpes zoster, and pneumococcal disease for all adults 65 years old or older.(89) 
Vaccine-specific recommendations are complicated, change frequently, and are beyond the scope 
of this narrative, however the general recommendations are as follows. Influenza vaccine should 
be administered annually. Tetanus, diphtheria, and pertussis (Tdap) vaccine should be 
administered once during adolescence or adulthood with Td boosters every ten years; with Tdap 
to replace one Td. The Zoster vaccine available during this study (Zostavax) should be 
administered once at age 50 years or older. The two pneumococcal vaccines, PPSV13 and PPSV23 
should be administered to all adults age 65 years and older. 
Though other vaccines may be indicated by patient-specific health conditions, 
generalizable targets can be established for the prior list of recommended immunizations. In the 
65 year and older age group, the 4PPTP allows the tracking of pre/post rates for the following 
vaccines: influenza, Tdap, PCV, PPSV, Zoster, and Hep B. The ideal measure of immunization 
rates is the ratio of patients eligible for a specific vaccine who have received that vaccine to those 
who are eligible and have not yet received the vaccine. However, because the classification of 
eligibility requires access to patient health records, the 4PPTP makes no attempt to determine 
eligibility and computes or accepts pre/post rates as supplied by the participant. The software can 
compute rates from data provided during a manual review of charts from a sample of the patient 
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panel within the age group or can be entered directly if the rate is computed elsewhere, for 
example, in the electronic health record. 
The pneumococcal vaccines pneumococcal conjugate vaccine (PCV) and pneumococcal 
polysaccharide vaccine (PPSV) present an interesting modeling challenge. As discrete vaccine 
administrations with non-overlapping serotype protection, they could be modeled as separate 
events. However, the administration guidelines which are governed by immunologic response and 
patient safety dictate that these vaccines should not be administered within the same year. 
Consequently, this relationship between the two vaccines needs to be reflected in model logic. 
Since the expected duration of the intervention is less than one year, the model assumes that both 
vaccines have been or will be administered as a two-dose series and evaluates the rate of 
pneumococcal vaccination as the average of the PCV and PPSV rates.  
Accurately measuring influenza vaccination rates as flu season begins or ends can also 
become problematic. If the intervention spans either time, determining eligibility is nuanced. For 
example, should a practitioner consider a non-immunized patient eligible or ineligible on April 1? 
Such a determination requires knowledge of the prevalence of the annual epidemic. This model 
assumes that participants will naturally avoid this issue by not targeting influenza improvement 
when the intervention is conducted outside of the annual flu season.  
Zoster vaccination policy presents additional modeling challenges in the study population. 
The tabulation of Zoster rates seems to be the most straight-forward computation. However, this 
apparent simplicity is undermined by provider and/or patient behavior. The high cost of the vaccine 
and complicated reimbursement schemes frequently result in a referral to pharmacies for 
administration. In these cases, the administration may not be recorded in the medical record or the 
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patient may fail to follow up on the referral. As with influenza, this model assumes that physicians 
who are not prepared to administer zoster, will not choose to target the rate for improvement.  
Computing zoster-related parameter estimates was an additional complication addressed in 
this analysis. Zoster vaccine has been recommended for healthy adults 60 years of age and 
older.(90) This recommendation is logical given the presentation of the disease but a non-typical 
cohort for epidemiologic analysis. Therefore, model parameters for 60-65-year-old individuals, 
were developed by applying age-specific data reported in early clinical trials of the vaccine with 
epidemiologic surveillance data typically reported in two cohorts of adults divided at age 65 years. 
These transformations and assumptions are described further below. 
Vaccination costs are also readily available. The annual vaccine price list published by the 
Centers for Disease Control (CDC) and a search of the Centers for Medicaid Services (CMS) 
physician fee schedule report the required parameters for both the CDC contract and private sector 
prices.(91, 92) The public contract price is used for all public insurance programs (i.e. Medicaid 
and Medicare) and grant-funded immunization efforts. Private sector costs are reported annually 
to the CDC by vaccine manufacturers. As vaccination of nearly all US seniors is covered by 
Medicare, the model uses CDC contract prices. 
3.2.2  Disease Dynamics 
The 4PPTP does not alter the outcomes associated with infection directly. Rather, the 
program seeks to prevent cases of disease through increased vaccination. This model compares the 
incremental costs and benefits of a national implementation of the program over a 10-year time 
horizon. This duration corresponds to the ages 65-75 years where parameter estimates are most 
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stable. As individuals age beyond 75 years old, vaccine effectiveness is less consistent and robust 
due to comorbid conditions and immunesenescence.(93, 94) 
Routine population surveillance provides estimates of disease prevalence. Though 
immunologic response can be individually variable and can impact susceptibility, it was assumed 
that prevalence is generally consistent over time and predicted by vaccine uptake. In the base case, 
the model used the prevalence of disease observed in prior seasons. In the experimental case, 
prevalence is adjusted by the increase or decrease of vaccine coverage attributed to the 
intervention. 
The consequences of infection by each VPD are well-studied. Estimates of the likelihood 
of disease-specific complications are available in pre-licensure vaccine effectiveness (VE) studies 
and frequently can be derived from population surveillance data as well. The model considers each 
outcome as a binary decision where the probability of each complication is governed by Bayesian 
inference. Outcomes in this model, are assumed to be independent of factors that cross VPD and 
are attributed solely to the natural progression of disease and intervention effects. For example, 
infection by one VPD is assumed to be unrelated to infection by other VPD. 
In addition to monetary costs associated with VPD, disease prevention strategies, 
treatments and outcomes are also parameterized by their experiential cost expressed as the increase 
or decrease of quality adjusted life years (QALY). This analysis uses a weighted average life 
expectancy for the 65 year and older cohort from US census cohort age distributions.(95) All 
QALY adjustments for modeled factors are made relative to this baseline value. Some factors (for 
example, receiving a vaccine) have a minimal QALY cost per individual as the procedure requires 
little time and inconvenience. Other factors (for example, death) have a potentially large QALY 
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cost as the reduction of life years is absolute. Values for each factor included in the model were 
available from the literature. 
3.2.3  Intervention Dynamics 
At the clinical level, the 4PPTP operates through multiple pathways simultaneously 
however, these intra-intervention dynamics were not modeled. Because participants are allowed 
to customize the intervention, capturing the effect of any single intervention strategy is impractical. 
Moreover, modeling the interactive dynamics among selected strategies would not necessarily add 
clarity to the outcome in the form of the incremental cost effectiveness ratio. These effects were 
assumed to be captured in the cost of the intervention and the increase or decrease in vaccination 
rates. Therefore, the experimental condition differed from the base case only in vaccination uptake.  
To estimate the effect of the intervention, the observed differences in pre/post rates of 
vaccination from the ABFM PPM intervention were added to the base case vaccination rates. The 
modified values were substituted as the experimental probability of vaccination in the alternative 
strategy arm. All other dynamics were identical between arms.  
3.2.4  Simulation Environment 
The analysis uses the societal perspective following the guidelines for cost-effectiveness 
analyses by the Second US Panel on Cost-Effectiveness in Health and Medicine.(96) Relevant 
health effects and costs occurring during the time horizon were included in the model regardless 
of payor. Secondary effects such as herd immunity and non-healthcare outcomes including 
alterations to productivity, consumption and outcomes in other economies were not modeled. Non-
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monetary costs such as the perceived inconvenience of disease and complications were aggregated 
through utility values into a net change in quality adjusted life years.  
The primary analytic outcome was the incremental cost effectiveness ratio (ICER) which 
represents the difference between the cost per QALY of the intervention arm and the reference 
arm. The evaluation of cost-effectiveness for each strategy was computed as the ratio of the sum 
of the accrued costs of the program, vaccination and illnesses to the sum of the accrued QALY 
lost for the same. Prior to analysis, a willingness to pay value of $100,000 per QALY was accepted 
as the threshold for a determination of cost effectiveness for the favored strategy. Thus, the 
intervention would be considered a good value at a societal level if its ICER were greater than the 
base case and if the program cost less than $100,000 per QALY. The study population was 
composed of two identical hypothetical cohorts of greater than 65-year-old US adults. Population 
characteristics including age distribution and life expectancy were extracted from US census data.  
The complete model and supporting documentation are available online at 
https://github.com/PittVax/4PillarsCEA_over65. As shown in a simplified diagram of the decision 
tree in Figure 8, the two cohorts entered the model with the assignment of vaccination status for 
each vaccine. The proportion of individuals receiving each combination of vaccines was computed 
using the product of the fractional probabilities of accepting each vaccine. Likelihood values for 
influenza, pertussis and herpes zoster vaccination required no transformations. Likelihood of 
pneumococcal vaccination was modeled as the average of the probabilities of receiving PCV and 
PPSV.  
Only the likelihoods of vaccination differed between the arms. In the intervention arm, the 
observed average percentage point increase/decrease from baseline in the ABFM PPM data was 
added to rates used in the reference arm. After vaccine status was assigned, infection from each 
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illness was determined using reported VE and the annual likelihood of infection computed for each 
VPD. All related health outcomes were assessed for those infected. Outcomes for each branch 
were computed as the ratio of the sum of the costs associated with: the program, illnesses, 
complications, and vaccinations to the sum of QALY lost.  
 
Figure 8 Simplified View of Tree Structure 
3.2.5  Model Parameters 
Model parameter values were sourced from public databases and the medical economic 
literature as enumerated in Table 3. When appropriate, values were converted to a reference year 
of 2015 and future values were discounted at 3% per year. All parameters were varied widely in 
sensitivity analyses. Monetary costs of the program, vaccinations, illnesses and complications 
were measured in 2015 US dollars. Non-monetary outcomes were measured in QALY lost. 
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Table 2 Model Parameters 
     Value Low High Distribution Reference 
Costs (base year 2015), $ 
   
 
 
 Disease  
   
 
 
  Herpes zoster 
   
 
 
   Acute - inpatient 8745.24 7923.63 10195.49 Gamma (97) 
   Acute - outpatient 348.30 268.21 512.14 Gamma (97) 
   Herpes zoster oticus 433.26 121.36 849.52 Gamma (97) 
   Ocular complications 13659.12 11231.91 16086.33 Gamma (97) 
   Post-herpetic neuralgia 686.90 586.17 816.76 Gamma (97) 
  Influenza      
   Influenza (average, all 
severities) 1655.00 432.00 3706.00 Gamma (85) 
  Pertussis      
   Mild pertussis, when treated 305.00 153.00 1525.00 Gamma (85) 
   Moderate pertussis 424.00 212.00 2120.00 Gamma (85) 
   Severe pertussis 7824.00 4000.00 11500.00 Gamma (85) 
     
     
  Pneumonia      
   Invasive pneumococcal disease      
    Disabled 32795.00 26236.00 39354.00 Gamma (98) 
    Invasive pneumococcal 
disease 26031.72 20825.00 31238.00 Gamma (98) 
   Nonbacteremic pneumococcal 
pneumonia      
    Hospitalized 16671.00 13337.00 20005.00 Gamma (98) 
    Outpatient 587.00 470.00 704.00 Gamma (98) 
 Implementation program, per eligible 
person 1.78 0.70 2.26 Gamma (85) 
 Vaccines      
  Herpes zoster - Zostavax 187.89 150.00 225.00 Gamma (99) 
  Influenza - Fluzone 10.69 6.64 32.75 Gamma (85) 
  Pneumococcal conjugate - Prevnar 
13 TM 159.60 96.10 220.00 Gamma (85) 
  Pneumococcal polysaccharide - 
Pneumovax23 78.90 26.60 130.00 Gamma (85) 
  Tdap - Boostrix 37.55 20.18 42.61 Gamma (85) 
  Vaccine administration, per 
vaccine 25.51 20.00 30.00 Gamma (85) 
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Table 2 Continued 
Duration, Days      
 Herpes zoster      
  Acute infection 21.00 14.00 28.00 Poisson (100) 
  Hospitalization 4.80 4.50 5.40 Poisson (97) 
  Post herpetic neuralgia 60.00 30.00 120.00 Poisson (100) 
 Pertussis 87.00 30.00 100.00 Poisson (85) 
 Pneumonia      
  Invasive pneumococcal disease 27.00 20.00 40.00 Poisson (85) 
  Nonbacteremic pneumococcal 
pneumonia      
   Hospitalized 27.00 20.00 40.00 Poisson (85) 
   Outpatient 18.00 10.00 25.00 Poisson (85) 
Probabilities      
 Herpes zoster      
  Case-mortality per 100,000 10.16 5.08 15.24 Beta (101) 
  Complications      
   Any ophthalmic complications 0.0220 0.0120 0.0320 Beta (97) 
   Herpes oticus 0.0020 0.0000 0.0050 Beta (97) 
   Monaural deafness, given 
herpes oticus 0.0690 0.0130 0.1200 Beta (97) 
   Monocular blindness, given 
ophthalmic complications 0.0390 0.0110 0.0670 Beta (97) 
   Post herpetic neuralgia >70 0.5600 0.3500 0.7500 Beta (97) 
  Hospitalization 0.0180 0.0050 0.0680 Beta (102) 
 Influenza      
  Case-hospitalization 0.0421 0.0140 0.0700 Beta (85) 
  Case-mortality per 100,000 1170 370 2000 Beta (103) 
 Pertussis      
  Relative likelihood of treatment 
(vs no treatment) 0.7070 0.5000 0.9000 Beta (85) 
  Severity relative likelihood      
   Encephalopathy, given severe 0.0143 0.0000 0.0300 Beta (85) 
   Moderate 0.7400 0.6300 0.8500 Beta (85) 
   Mortality, given severe 0.0086 0.0000 0.0200 Beta (85) 
   Severe (hospitalized) 0.1200 0.0600 0.1800 Beta (85) 
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Table 2 Continued 
 Pneumonia      
  Invasive pneumococcal disease      
   Case-mortality 0.2000 0.1000 0.3000 Beta (98) 
   Disabled 0.0610 0.0305 0.0915 Beta (98) 
  Nonbacteremic pneumococcal 
pneumonia      
   Case-mortality 0.0730 0.0365 0.1095 Beta (98) 
   Relative likelihood of outpatient 
treatment (vs inpatient) 0.8310 0.7000 0.9600 Beta (85) 
 Probability of illness without vaccinations (yearly)     
  Herpes zoster 0.0114 0.0050 0.0160 Beta (104) 
  Influenza 0.0900 0.0660 0.1140 Beta (103) 
  Invasive pneumococcal disease 0.0002 0.0000 0.0007 Beta (85) 
  Nonbacteremic pneumococcal 
pneumonia 0.0378 0.0054 0.1210 Beta (85) 
  Pertussis 0.0026 0.0014 0.0046 Beta (85) 
 Probability of vaccination      
  Absolute increase in vaccine uptake with 
program     
   Herpes zoster 0.0802 0.0000 0.1203 Beta Data 
   Influenza 0.1116 0.0000 0.2200 Beta Data 
   Pneumococcal vaccines 0.1742 0.0000 0.3400 Beta Data 
   Tdap 0.1654 0.0000 0.2200 Beta Data 
  Before program      
   Average of PCV PPSV 0.6279 0.3100 0.8090 Beta Data 
   Herpes zoster 0.4464 0.2200 0.6600 Beta Data 
   Influenza 0.6616 0.3600 0.7400 Beta Data 
   Tdap 0.4965 0.2500 0.7500 Beta Data 
Disutilities (QALY lost)      
 Illness death (discounted) 10.25 5.00 15.00 Gamma (85) 
 Influenza      
  Hospitalized 0.042 0.020 0.08 Gamma (85) 
  Outpatient 0.002 0.00 0.02 Gamma (85) 
Utilities      
 Pertussis      
  Mild 0.90 0.99 0.80 Gamma (85) 
  Moderate 0.85 0.95 0.75 Gamma (85) 
  Severe 0.81 0.90 0.60 Beta (85) 
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Table 2 Continued 
 Herpes zoster      
  Acute - outpatient 0.022 0.011 0.03 Beta (97) 
  Monaural deafness 0.97 0.96 0.98 Beta (97) 
  Monocular blindness 0.92 0.88 0.96 Beta (97) 
  Post herpetic neuralgia 0.67 0.63 0.70 Beta (97) 
 Nonbacteremic pneumococcal 
pneumonia      
  Disability post pneumococcal 
disease 0.40 0.20 0.60 Beta (85) 
  Inpatient 0.20 0.00 0.50 Beta (85) 
  Invasive pneumococcal disease 0.20 0.00 0.50 Beta (85) 
  Outpatient 0.90 0.70 1.00 Beta (85) 
 Pertussis      
  Encephalopathy 0.20 0.00 0.40 Beta (85) 
Vaccine effectiveness      
 Influenza 0.59 0.20 0.67 Beta (85) 
 Pneumococcal illness serotype 
prevalence      
  13-valent pneumococcal conjugate 
vaccine serotypes 0.31 0.00 0.50 Beta (85) 
  23-valent pneumococcal 
polysaccharide vaccine serotypes 0.68 0.50 0.85 Beta (85) 
 Pneumococcal vaccines (10-year 
average)      
  Invasive pneumococcal disease 0.54 0.40 0.68 Beta (85) 
  Nonbacteremic pneumonia 0.38 0.28 0.48 Beta (85) 
 Tdap (10-year average) 0.25 0.00 0.95 Beta (85) 
 Zoster  0.26 0.13 0.38 Beta (102) 
3.2.5.1  Costs 
The costs associated with each VPD were found in the literature. Likelihood of infection 
was assumed to be related only to vaccination and vaccine effectiveness and assumed to be 
uncorrelated with other infections. Influenza infection could result in outpatient treatment, 
hospitalization, or death. Recovered individuals were assumed to suffer no long-term 
complications. Pneumococcal disease was modeled in two branches. Invasive pneumococcal 
disease (IPD) resulting in outpatient treatment, hospitalization and disability or death and non-
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bacteremic pneumococcal pneumonia (NPP) which could lead to outpatient treatment or 
hospitalization and recovery, disability or death. Pertussis resulted in mild and moderate infections 
with recovery, or severe infections leading to recovery, encephalopathy or death. Finally, Zoster 
infection was modeled with branches for outpatient treatment, hospitalization and complete 
recovery, hospitalization and death, or hospitalization and recovery with complications including 
post-herpetic neuralgia, monocular blindness and monaural deafness. 
Program costs were estimated through a survey of participants in a randomized controlled 
trial of the 4PPTP who valued the personnel and material costs associated with the 
intervention.(85) Though the self-directed ABFM PPM version of the program was of a shorter 
duration and required no interaction with the program administrators, costs were assumed to be 
equal to those of the clinical trial. This conservative assumption biases against the value of the 
intervention.  
As most of the vaccines administered to older adults are paid by Medicare, the CDC 
contract price of each vaccine, except zoster, was used for vaccine cost. The private sector price 
was used for Zoster which is only covered by Medicare part D and has complex reimbursement 
guidelines which often result in patients 65 years and older paying retail cost for the vaccine. Over 
the 10-year time horizon, Tdap and Zoster vaccine are charged once. Influenza vaccine is charged 
annually and discounted at 3%. The pneumococcal vaccines PCV and PPSV are assumed to be 
given in a two-dose series resulting in two administration fees and the cost of each vaccine for 
those who receive the vaccine. Co-administration of vaccines would reduce the cost of the 
intervention. Therefore, to bias against the intervention, vaccines were assumed to be administered 
individually and assigned an administration fee per vaccine.  
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3.2.5.2 Probabilities 
Vaccines 
Vaccination probabilities, as presented in Table 3, were assigned using the data generated 
by participants in the ABFM PPM. Each subject is a physician leading a clinical practice through 
the implementation of the 4PPTP module in their 65 year and older patient panel. During 
enrollment, physicians chose which vaccines would be used as measures of quality improvement 
from the list of vaccines indicated for the selected patient age group. Following vaccine selection, 
physicians entered a baseline rate for each vaccine. At the end of the intervention, physicians 
entered a post-intervention rate for each selected vaccine.  
Table 3 ABFM PPM pre/post immunization rates by vaccine in 65+ year-old patients 
Vaccine Type Pre-Intervention Post Intervention Percentage Point Change N 
Tdap 49.7 66.2 16.5 29 
PCV 56.9 77.3 20.4 34 
PPSV 68.7 83.1 14.4 26 
Influenza 66.2 77.3 11.1 28 
Zoster 44.6 52.7 8.1 26 
 
The model uses pre-intervention rates as the likelihood of vaccination in the no-
intervention arm and adds the absolute percentage point change to these values in the experimental 
arm. This method allows for more plausible sensitivity testing as the experimental condition is 
varied relative to the baseline value. If the post-intervention rates were directly assigned to the 
intervention arm, sensitivity testing would evaluate improbable differences in before/after 
measurements. As noted above, in the absence of individual patient records, PCV and PPSV were 
modeled as a two-dose series with rates computed as the average of the baseline (0.6279) and 
follow-up (0.8021) vaccination rates. For patients in the branches where pneumococcal vaccine 
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was assigned, it was assumed that both vaccines would be administered. This assumption was 
tested widely in sensitivity analyses. 
The likelihood of infection for the population in each branch was determined by evaluating 
vaccination status and then applying protection through vaccine effectiveness on appropriate 
branches. Table 4 shows a truth matrix for the 16 possible branches. The overall probability for 
each combination of vaccines was determined by calculating the product of the individual 
probabilities of receiving each vaccine. For example, the likelihood of receiving all four vaccines 
is expressed as follows: 
𝑝𝑝𝐴𝐴𝐴𝐴𝐴𝐴 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 =  𝑝𝑝𝐹𝐹𝐴𝐴𝐹𝐹  ∗  𝑝𝑝𝑇𝑇𝑇𝑇𝑣𝑣𝑇𝑇  ∗  𝑝𝑝𝑇𝑇𝑣𝑣𝑣𝑣𝐹𝐹𝑝𝑝𝑝𝑝  ∗  𝑝𝑝𝑧𝑧𝑝𝑝𝑣𝑣𝑧𝑧𝑣𝑣𝑧𝑧 
The likelihood of receiving none of the four vaccines is expressed as follows: 
𝑝𝑝𝑁𝑁𝑝𝑝 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 = (1 − 𝑝𝑝𝐹𝐹𝐴𝐴𝐹𝐹)  ∗ (1 − 𝑝𝑝𝑇𝑇𝑇𝑇𝑣𝑣𝑇𝑇)  ∗ (1 − 𝑝𝑝𝑇𝑇𝑣𝑣𝑣𝑣𝐹𝐹𝑝𝑝𝑝𝑝)  ∗ (1 − 𝑝𝑝𝑧𝑧𝑝𝑝𝑣𝑣𝑧𝑧𝑣𝑣𝑧𝑧) 
Table 4 Truth table of vaccination status 
Vaccines Influenza Tdap Pneumococcal Zoster 
None No No No No 
Zoster No No No Yes 
Pneumococcal No No Yes No 
Pneumococcal, Zoster No No Yes Yes 
Tdap No Yes No No 
Tdap, Zoster No Yes No Yes 
Tdap, Pneumococcal No Yes Yes No 
Tdap, Pneumococcal, Zoster No Yes Yes Yes 
Influenza Yes No No No 
Influenza, Zoster Yes No No Yes 
Influenza, Pneumococcal Yes No Yes No 
Influenza, Pneumococcal, Zoster Yes No Yes Yes 
Influenza, Tdap Yes Yes No No 
Influenza, Tdap, Zoster Yes Yes No Yes 
Influenza, Tdap, Pneumococcal Yes Yes Yes No 
Influenza, Tdap, Pneumococcal, Zoster Yes Yes Yes Yes 
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Infection was determined according to each disease’s attack rate in the population aged 65 
years and older. Protection from illness through vaccination was included for appropriate branches 
by multiplying the illness attack rate by one minus VE. Illness probabilities were transformed to 
annual probabilities where necessary by converting to rates, adjusting by the 10-year time horizon 
and then converting to annual probabilities.  
Attack rates and vaccine efficacies for influenza, pneumococcal disease and pertussis in 
the population were found in recently published estimates in the medical literature.(85) As with 
other herpes Zoster parameters, attack rate and VE were not available for the study population. To 
maintain consistency with the same decision for VPD-related illness outcomes, estimates for the 
70 year-old and older population were used.(104) The pneumococcal vaccines PPSV and PCV13 
offer protection for different viral serotypes which circulate at different rates in the population. It 
was assumed that PPSV offered protection against IPD and PCV13 against IPD and NBP. Though 
the likelihood of receiving either vaccine was averaged into a combined probability for 
pneumococcal vaccination, the individual efficacies and attack rates for IPD and NBP were used 
in assessing health outcomes. These assumptions were tested in sensitivity analyses. The efficacies 
of zoster, pertussis and pneumococcal vaccines have been shown to decline with increasing patient 
age.(105-109) This dynamic was included in the analysis by calculating average VE for the 
vaccines over the 10-year time horizon. 
Health outcomes 
When available, probability estimates were sourced from prior peer-reviewed modeling 
studies. However, estimates of zoster-related probabilities were unavailable in the study 
population. As noted earlier, the clinical trials which report the parameters for cost effectiveness 
modeling were conducted in a cohort of individuals selected by medical indication (>= 60 
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years)(104) rather than by the common demographic age definition for older adults (>=65 years). 
Consequently, these values incorporate the greatest number of assumptions. 
Because acute herpes zoster is rarely fatal, clinical trials of Zoster mortality in alternative 
cohorts would be cost-prohibitive and unlikely to yield significant information. In the absence of 
this epidemiologic data, zoster-related mortality was extracted from the CDC WONDER 
underlying causes of death database. For individuals 65-74 years in 2015 (27,550,517), 32 deaths 
included one or more of the ICD-10 codes: B02.0 (Zoster encephalitis), B02.1 (Zoster meningitis), 
B02.2 (Zoster with other nervous system involvement), B02.3 (Zoster ocular disease), B02.7 
(Disseminated zoster), B02.8 (Zoster with other complications), B02.9 (Zoster without 
complication).(110) Cases over age 74 years were excluded as the model time horizon is limited 
to 10 years. 
Prior cost-effectiveness studies of hypothetical herpes zoster vaccination strategies by age 
provided values for additional parameters by applying outcomes from observational studies and 
retrospective medical claims data analyses to age-stratified cohorts.(97) Herpes zoster 
complications included probabilities of ophthalmic complications (0.022), monocular blindness, 
given ophthalmic complications (0.039) herpes oticus (0.002), monaural deafness, given herpes 
oticus (0.069), and long-term post herpetic neuralgia (0.560).  
To facilitate comparison with observational data generated from the Shingle Prevention 
Study, (104) Rothberg, Virapongse (97) developed probability estimates for post herpetic 
neuralgia for the 60-69 and 70 year and older cohorts from data provided by a retrospective medical 
database extraction study. They noted that the estimates describing the younger cohort differed 
from those observed in the clinical trial. Therefore, the older population estimate was used in this 
model. Likewise, as developed in another study using similar methods, the probability of 
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hospitalization due to herpes zoster among those 70-79 years (0.018) was selected over the 
alternative (0.013) for those 60-69 years. (102)  
Well-documented estimates of other event probabilities for the population 65 years and 
older were available in the literature. Beginning with infection, each illness branch included the 
probability of developing clinically relevant sequela leading to either death or recovery. Death 
resulting from each illness is modeled as case-mortality within one year of infection. Survival was 
calculated as the complement to the Bayesian combination of all other outcomes. For example, 
given influenza infection, outpatient treatment and recovery (p=0.946) is the probability remaining 
after subtracting the probability of hospitalization and recovery (p=0.042) and hospitalization and 
death (p=0.012) from the total probability of any event (p=1.0). 
A statistical analysis of data reported from the National Center for Health Statistics and the 
National Hospitalization Discharge Survey Estimates provided probabilities of influenza-related 
outcomes. This analysis extended an established Poisson fitting algorithm(111) to a more sensitive 
sub-set of ICD-10 codes which was then fitted to a peri-season risk-difference model resulting in 
a point estimate of annual influenza case-fatalities of 1170 per 100,000, and a probability of 
hospitalization of 0.018. (103) 
Pneumococcal disease included two variations. Estimates of invasive pneumococcal 
disease (IPD) and nonbacteremic pneumococcal pneumonia (NBP) outcomes were compiled from 
simulation data provided with a cost-effectiveness analysis of 13-valent pneumococcal conjugate 
vaccine (PCV13).(98) Though more complex, using simulation output rather than observational 
data was necessary to cover all probabilities with more granularity than could be achieved with 
less specific clinical data. As is reflected in the data, the severity of a given pneumococcal infection 
is related to the patient’s overall health status. Thus, weighted averages for each clinical outcome 
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were calculated using the data stratified into low, medium and high-risk patient groups. Table 5 
summarizes the relevant values and computations. First, the total IPD rate was evaluated for each 
risk group by multiplying the population in each risk group by the sum of the bacteremia and 
meningitis rates. Next, the individual rates were used to generate the number of cases of meningitis 
and bacteremia in each risk group. These values were multiplied by the mortality rates to arrive at 
expected case-fatalities due to IPD. 
Table 5 Estimated invasive pneumococcal disease case-fatalities by risk group in 65-74 year old individuals 
 
65–74 years  
Low Risk Moderate Risk High Risk 
No. of US adults (in millions) 8.8 8 4.1 
Annual disease incidence (per 100,000) 
  
Bacteremia rate 4.30 16.90 69.00 
Meningitis rate 0.30 1.10 4.40 
IPD rate 4.60 18.00 73.40 
IPD cases 405 1440 3009 
Bacteremia 
   
 Cases 378 1352 2829 
Mortality 0.138 0.172 0.207 
Case-fatalities 52 233 586 
Meningitis 
   
 Cases 26 88 180 
Mortality 0.235 0.293 0.352 
Case-fatalities 6 26 64 
Total IPD case-fatalities 58 258 649 
 
Finally, the sum across the row for total IPD cases (4854) was divided by the sum across 
the row for total IPD case-fatalities (966) to obtain the weighted probability of death (0.20) due to 
invasive pneumococcal disease. Similarly, the weighted average of meningitis cases was 
calculated and used as the probability of IPD hospitalized recovery with disability (0.06). Infection 
71 
by IPD was assumed to include hospitalization, thereby assigning the hospitalized and recovered 
branch the remaining probability. 
3.2.5.3 Utilities and Durations 
Effectiveness was quantified through utility estimates. This strategy transforms each 
potential health state to a proportion of quality adjusted life years (QALY) to expected full quality 
life. For example, the utility of each herpes zoster complication was estimated in the randomized 
clinical trial of vaccine effectiveness where patients recorded daily pain using the worst-pain 
component of the herpes zoster brief pain inventory. (97) Investigators derived a total adjustment 
in quality of life for each condition, by statistically relating the zoster-specific pain measurements 
to the validated EuroQOL-5D inventory of patient utilities and then dividing the observation period 
by one year. The estimates show that post-herpetic neuralgia (PHN) is the most offensive non-fatal 
herpes zoster outcome and results in a quality adjustment of 0.67 of life quality. Similarly, acute 
outpatient infection is the least objectionable herpes zoster condition resulting in a quality 
adjustment of only 0.0216.  
Total effectiveness for each branch was calculated as the sum of QALY lost due to adverse 
health conditions in the branch. This computation required assigning an expected duration to each 
complication and then adjusting that time by the utility value. In this strategy, utility values are 
transformed to disutilities where 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 =  1 − utility and then converted to QALY with  
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 ∗  𝑑𝑑𝑑𝑑𝐷𝐷𝐷𝐷 𝑜𝑜𝑜𝑜 𝑐𝑐𝑜𝑜𝑐𝑐𝑑𝑑𝐷𝐷𝐷𝐷𝐷𝐷𝑜𝑜𝑐𝑐 365�  =  QALY lost For PHN, a utility of 0.67 (disutility of 0.33 
with 60 day duration) represents a reduction of 0.05 QALY or 19.8 days of a full quality life. As 
with other time-based measurements, it is necessary to discount future values. Each effectiveness 
estimate was discounted at 3% per year and assigned to appropriate branches.  
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Mortality was modeled with an identical strategy. The disutility of fatal outcomes was 
modeled as 100% loss of QALY over the duration of death where duration of death represented 
the life expectancy of the cohort. Life expectancy (77.19 years) was calculated as the weighted 
contribution of each year of life to total life years reported by the 2015 US census for the population 
65 years and older. Non-fatal chronic outcomes were assumed to endure over this remaining life 
expectancy. 
3.2.5.4 Sensitivity Analyses 
All parameters were subjected to sensitivity analysis over a broad range of values. In the 
deterministic base case analysis, high and low values were assigned to each parameter value as 
shown in Table 3. When possible, these values were extracted from the literature along with the 
parameter estimate. When unavailable, these values were calculated as ±20%-50% around the 
point estimate in accordance with the uncertainty of each estimate. The impact of each input was 
calculated by varying parameters individually and then computing the model for each value in the 
range. This technique estimates the total variability in model outcomes attributable to each 
parameter.  
A probabilistic sensitivity analysis was also conducted. This analysis varies all parameters 
with each calculation of the model. As shown in Table 6 an appropriately shaped distribution was 
assigned to each parameter type as recommended by the Panel on Cost-Effectiveness in Health 
and Medicine. (112) Each of these distributions was fit to the base case ranges by specifying a 
mean distribution location near the point estimate and a distribution spread covering the low and 
high range. The model was then run using parameter values randomly sampled from the associated 
distribution.  
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Table 6 Appropriate distributions by variable type for probabilistic sensitivity analysis 
Parameter Type Distribution 
Costs Gamma 
Utility/Disutility 
Probability 
Proportion 
Efficacy 
Beta 
Quantity Poisson 
 
The output from these preliminary runs was compared to the base case parameter values 
and distribution specifications were adjusted as necessary to match base case parameter ranges as 
closely as possible. A final run of 500 iterations using 500 sets of randomly selected values 
generated the average expected incremental cost-effectiveness ratio (ICER) for the two arms 
produced by each simulation.  
3.3 Results 
The 4PPTP was favored over the No-Program condition with an estimated cost per QALY 
of $4,927.10. In sensitivity testing, the model showed no threshold effects where individual 
parameters would be likely to alter the favorability of the strategies. Table 7 shows the incremental 
cost effectiveness ratio of the 4PPTP vs. No Program. The program cost was $32.63 more than 
standard treatment and saved 0.0066 QALY per individual at a value of $4927.10 per QALY 
saved.  
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Table 7 Base Case Cost effectiveness of the 4 Pillars™ Practice Transformation Program vs. No Program 
 Cost 
($) 
Effectiveness 
(QALY) 
Incremental 
Cost 
($) 
Incremental 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
No program 1998.54 -0.1094 0.0000 0.0000 0.0000 
Implementation 
program 
2031.17 -0.1028 32.63 0.0066 4927.10 
 
The predicted public health outcomes of the program are listed in Table 8. The model 
suggests that if the program were applied to a population resembling the 2015 US cohort of 
individuals 65 years of age or older, over 2.38 million cases of disease, 163,280 hospitalizations 
and 27,736 deaths would be averted over the 10-year time horizon.  
Table 8 Public health outcomes of 4 Pillars™ Practice Transformation Program for 65+ population over 10-
year time horizon 
 
 Expected Cases Averted Cases 
VPD Condition 
  
Influenza cases 17,778,792 -1,920,143 
hospitalizations 956,499 -103,304 
deaths 208,012 -22,466 
Pertussis cases 1,060,743 -48,430 
cases (mild) 148,504 -6,780 
cases (moderate) 786,044 -35,888 
cases (severe) 127,289 -5,812 
deaths 1,095 -50 
Pneumo NPP cases 14,058,218 -302,194 
outpatient 11,682,379 -251,123 
hospitalizations 2,375,839 -51,071 
deaths 173,436 -3,728 
Pneumo IPD cases 84,123 -6,935 
hospitalizations 84,123 -6,935 
deaths 16,825 -1,387 
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Table 8 Continued 
Zoster cases 4,572,212 -103,739 
outpatient 4,485,354 -101,768 
hospitalizations 86,859 -1,971 
HO deafness 630 -14 
blindness 3,919 -89 
PHN 2,557,839 -58,035 
deaths 4,642 -105 
3.3.1  Sensitivity Analysis 
In one-way sensitivity testing, the model was very stable with no features resulting in 
dominance of the experimental arm. This result is pictured in Figure 9, a tornado diagram of the 
features with cumulative risk > 99%. 
 
Figure 9 Tornado Diagram of ICER for Implementation Program vs. No Program X axis = willingness to pay 
per QALY, bands = uncertainty by parameter 
Fourteen features account for 99% of the variability in the model with the top five features 
representing 90% of uncertainty. Influenza-related parameters produced the largest variability in 
outcomes with the absolute increase in influenza vaccine uptake with the program potentially 
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increasing the ICER to $31,826/QALY and average influenza illness costs potentially reducing the 
ICER to -$8,905/QALY making the program cost-saving. Influenza vaccine effectiveness was also 
a key driver of cost potentially raising the ICER to $20,894/QALY when the vaccine is least 
effective. Case-mortality, virulence and vaccine cost also contribute to the 89% of variance 
attributable to influenza-related factors.  
Pneumococcal disease drives the second most influential cluster of factors. The total 
uncertainty from this cluster accounts for 7.6% of potential variability in the ICER and no single 
factor would be likely to shift the intervention to cost saving. Similar to influenza, epidemiologic 
factors (NBP virulence and 13-valent prevalence), treatment costs (NBP severity, vaccine costs) 
and increases in pneumococcal vaccination rates contribute to potential changes in the ICER. 
Combined, the estimation of the disutility of death and changes in herpes zoster vaccination rates 
account for 2.3% of uncertainty in the ICER. Neither factor would be likely to change the 
favorability of the program. 
A Monte Carlo probabilistic sensitivity analysis was conducted. Over 500 iterations, the 
program was the favored strategy with an average cost per QALY of $3,846.09 as shown in Table 
9. The cost estimation for the implementation program strategy ranged from $1,087.75 to 
$3,690.19 (median = $1,899.08) and $1,021.34 to $3,732.54 (median=$1,861.36) for the no-
program strategy. Effectiveness estimates ranged from -0.2818 to -0.0348 (median= -0.0960) for 
the 4PPTP strategy and -0.2945 to -0.0428 (median= -0.1036) for the no-program strategy. 
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Table 9 Cost effectiveness of the 4 Pillars™ Practice Transformation Program vs. No Program from Monte 
Carlo Simulation 
 
Cost ($) Effectiveness 
(QALY) 
Incremental 
Cost ($) 
Incremental 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
No 
program 
1923.42 
(SD=397.13) 
-0.1066 
(SD=0.0271) 
0.0000 0.0000 0.0000 
4PPTP 1950.82 
(SD=382.86) 
-0.0995 
(SD=0.026) 
27.39 0.0071 3846.09 
 
Over the 500 iterations, the intervention arm was strongly favored for all willingness-to-
pay values above $20,000. The cost effectiveness acceptability curve shown in Figure 10 displays 
minimal uncertainty in the model outcomes across the simulation suggesting that the model would 
predict similar results even when base case parameters are altered within expected ranges.  
 
Figure 10 Cost effectiveness acceptability curve of Monte Carlo simulation results showing the number of 
iterations where each strategy was favored at willingness-to-pay values < $100,000 QALY 
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3.4 Discussion 
The model estimated the value of the 4PPTP using two outcomes: 1. the estimation of the 
incremental cost effectiveness ratio and 2. the estimation of public health outcomes. The ICER 
represents the difference between the ratios of expected cost to expected effectiveness for the 
program vs. the base case and other strategies. This value is expressed in $/QALY. While it has 
no absolute meaning, the ICER provides a standardized unit by which health interventions can be 
compared. The ideal, though uncommon, result is an intervention that is both less expensive and 
more effective than the standard treatment. Such an intervention is said to be cost saving. An 
equally conclusive result is represented by dominated strategies. A strategy is said to be dominated 
when it is more expensive and less effective than alternative treatments. All other strategies are 
therefore more effective and more expensive than the standard treatment and can be ordered by 
ICER. Though often debated, European health agencies frequently consider interventions with a 
non-dominated ICER of $50,000/QALY to be good value while US agencies often use a more 
generous valuation of $100,000/QALY.  
Estimation of public health impact, a second experimental outcome, is frequently helpful 
in considering population-level policy decisions. In addition to the tabulation of cost and 
effectiveness for each branch, the model also tracked incidence of outcomes in the study 
population. Multiplying this observed incidence in the No-Program arm by census estimates, 
results in baseline incidence of each outcome produced by standard practice. Similarly, computing 
incidence in the intervention arm allows for comparison of cases averted by the experimental 
strategy. Although interpretation of these estimates is colored by ethical considerations, the 
magnitude of total number of cases averted in the context of the total population does offer useful 
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insight into the possible scope of an intervention. Presently, there are no conventions for 
interpretation of these estimates. 
Analysis of the outcomes data collected from the 4PPTP for immunization ABFM PPM, 
suggest that the program is a cost-effective intervention to increase vaccination rates in the primary 
care setting with clear public health benefits. Rates of vaccination increased across all measured 
immunizations with percentage point increases ranging from 8.1 for herpes zoster vaccine to 17.4 
for pneumococcal vaccines. Using a societal perspective, the program was favored over standard 
practice as measured prior to the intervention and resulted in the gain of 0.0066 QALY (2.40 days) 
at a cost of only $4,927/QALY. When extrapolated to the population 65 years of age or older, the 
program would avert over 2.38 million cases of disease, 163,280 hospitalizations and 27,736 
deaths over a 10-year time horizon.  
Sensitivity analyses showed that the program would likely remain the favored strategy with 
a willingness-to-pay between $5,000 (p=.53) to $20,000 per QALY (p=.99) and was very strongly 
favored above $20,000 per QALY (p>.99). The most influential drivers of uncertainty in the model 
were related to influenza epidemiologic dynamics, which accounted for 89% of total uncertainty. 
Increased influenza vaccine uptake had the greatest leverage in the model. This is not surprising 
for two reasons. First, as an annual vaccine, over the 10-year time horizon, influenza-related effects 
could be replicated up to 10 times. Secondly, uptake is correlated with the opposing dynamics of 
vaccination costs vs the costs of disease where effectiveness is also related to broad ranges of 
seasonal variability in vaccine effectiveness, disease infectivity and virulence. Combined, the 
uncertainty of each of these dynamics and the potential cumulative frequency of annual effects 
leads to the least predictable behavior in the model. A similar pattern was also evident in 
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pneumococcal-related factors where uptake, vaccine cost, infectivity and vaccine effectiveness all 
interact to contribute uncertainty, albeit with a much smaller combined effect than influenza. 
Limitations exist. As with all modeling analyses, parameter estimates can be imprecise and 
often represent dynamics which have not been directly studied. In this model, factors related to 
herpes zoster were extrapolated from the best available data in the absence of clinical trials in the 
experimental cohort. Some secondary effects such as herd immunity and susceptibility to 
coinfection were also excluded from the model to improve interpretability and clarity.  Likewise, 
pneumococcal vaccination was collapsed into an assumed two-dose series to best fit the available 
outcomes data. It is possible that relaxing this assumption with more specific outcomes data may 
reduce uncertainty. Public health outcomes should be interpreted with caution. Total cases were 
derived from US census data; however, the experimental strategy targets primary care physicians 
and individuals without a primary care provider would not benefit from the program. Finally, the 
limited sample size using self-reported outcomes data only suggests what might be observed in a 
population-wide deployment of the program. 
Unlike the calculation of immunization rates which is influenced by the modeling 
assumptions described above, VE is an uncomplicated algebraic operation. As all vaccines are 
thoroughly tested and monitored through clinical research trials and ongoing population 
surveillance, the modeling of VE is simply the likelihood of infection given vaccination. 
Complexity arises however, when VE is unknown in a population; for example, when a model 
considers a hypothetical extension of the ACIP recommendation to a new population, variations 
in vaccine production runs or distribution stress, or when VE is affected by another factor, such as 
waning immunity over time. Circumstances such as these are not modeled in this analysis.  
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Despite these limitations, the model proved to be robust and was tested with a wide range 
of potential values. The results strongly suggest that the 4 Pillars™ Practice Transformation 
Program for immunization is a cost-effective strategy to decrease the burden of vaccine 
preventable disease in the US population of older adults. Increased adoption of the program is 
advisable. 
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4.0 Implementation of the 4 Pillars™ Practice Transformation Program as a Quality 
Improvement Initiative 
The 4PPTP was pilot tested as a quality improvement initiative in the primary care division 
of a large regional health system. This opportunity drove further innovation in program design as 
well as significant learning about the differences between the dynamics of a clinical trial and the 
realities of interventions executed outside of a laboratory environment. Despite positive feedback 
from all stakeholders, significant changes in outcome measures were not detected in the available 
data. The following chapter discusses the implementation of the program, summarizes outcomes 
and discusses potential drivers of the results. Opportunities for improvement in future efforts to 
increase vaccination rates through primary care practices are proposed. 
4.1 Introduction 
For any intervention to confer benefits to a population, the intervention must be 
implemented at scale. This process of translation from the research laboratory to the “real world” 
is challenging and outcomes may differ dramatically from what was achieved in carefully 
controlled conditions. While the effectiveness of many health interventions can be maximized 
through technical or physical processes, interventions which depend on the alteration of behavior 
are subject to additional sources of uncertainty that may not be easily anticipated during 
translation. Despite careful preparation and additional tailoring of the program, these behavioral 
factors may have interfered with program fidelity. 
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The effectiveness trial was initiated at the request of the executive leadership of a large 
regional health system to address a perceived opportunity to improve adult immunization rates 
within their patient population. After several stakeholder meetings, all decisionmakers agreed to 
develop a customized version of the existing 4 Pillars™ intervention and to implement the new 
product in phases throughout the adult primary care practices of the health system. At the 
conclusion of the trial, 63 practices completed the intervention to improve measures of the adult 
vaccinations for; seasonal influenza (Flu), pneumococcal (Pneumo) & pneumococcal conjugate 
(PCV), tetanus-diphtheria (Td) & tetanus-diphtheria-pertussis (Tdap), and herpes zoster (Zoster). 
Analysis of variance testing of the practices’ before and after vaccination rates and missed 
opportunities to vaccinate did not reveal significant differences among the groups. 
4.2 Methods 
4.2.1  Implementation Methods 
The implementation team drew heavily from the theoretical models presented in chapter 
1.0 to translate the clinically efficacious 4PPTP to a more generalizable version. At the macro 
level, the process followed the Implementation Stages of exploration, installation, initial 
implementation, and full implementation as described in section 1.1.5.1. During this process, the 
existing software and deployment plan were customized through a series of stakeholder meetings, 
planning sessions and a pilot trial within a subset of the practices. A working group was formed 
and populated by both internal and external stakeholders. Internal members from the health care 
organization included executive leaders, members of the organization’s quality, operations, and 
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data departments, medical directors, practice managers, nursing supervisors and practice 
physicians. The external implementation team included educators from a pharmaceutical company 
and the authors of the 4 Pillars™ program and support staff.  
During the exploration stage the working group focused on knowledge transfer from each 
of the component teams. The organization presented their best estimates of current vaccination 
measures, available resources and desired outcomes from the proposed quality improvement 
program in vaccination. Representatives from the pharmaceutical company, shared a successful 
program which was implemented in a similar health care organization and committed to providing 
personnel to help implement the program. The 4 Pillars™ team presented the successful clinical 
trial outcomes and demonstrated the software and program design. The working group agreed to 
implement the 4PPTP throughout the organization’s practices in phases; where the first phase 
would serve as a pilot to reveal any issues that may need to be resolved before full deployment. 
In preparation for the pilot phase, the working group met as needed to identify and address 
potential threats to the program. All parties agreed that the engagement of practice staff would be 
critical and that enrollment in the program would need to be carefully scripted. The resulting three 
meeting enrollment protocol replicated the first three stages of implementation at the practice level. 
(See 1.1.5.1) This enrollment protocol began with a memorandum from the organization CEO to 
the practice staff as displayed in Appendix A. Subsequently, the following meetings were 
scheduled by an educator from the pharmaceutical company (Facilitator) with practice staff and a 
designated Immunization Champion (IC). 
1. Practice Leadership Meeting - On site meeting with Facilitator and practice 
leadership during a normally scheduled monthly meeting. 
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a. Pre-Intervention Self-Evaluation - Independent self-evaluation of 
practice readiness for change and baseline data collection (see A.2) 
2. Immunization Champion Coaching Meeting - On site meeting between 
Facilitator and Immunization Champion to review outline of the 
intervention and to prepare the Immunization Champion for the staff 
meeting 
3. All Staff Kick Off Meeting - On site meeting led by office manager & 
Immunization Champion supported by the Facilitator to kick off the 
intervention. 
Upon completion of the enrollment protocol, the Facilitator prepared the practice to 
complete iterative Plan, Do, Study, Act (PDSA) cycles of quality improvement in a coaching 
meeting with the Immunization Champion. The PDSA framework was selected from other similar 
models for its common usage in other medical quality improvement interventions and familiarity 
among medical professionals. The cycles were outlined as follows: 
1. Monthly PLAN step 
a. IC and Facilitator review a section of the 4 Pillars™ Vaccine 
Administration Readiness Questionnaire, immunization data, and/or 
Nurse Practice Inventory. 
b. Identify strategies from the toolkit to implement during the month 
with documented SMART goals to bring the plan to the other office 
staff 
c. Schedule DO touch point within a week 
d. Schedule STUDY touch point prior to next monthly staff meeting 
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2. Monthly DO step 
a. IC implements SMART goals contacting facilitator as necessary 
b. IC and Facilitator review SMART goals within a week and make 
changes to the goals as necessary 
3. Monthly STUDY step 
a. IC and Facilitator review SMART goals and successes/challenges 
from DO step 
b. IC and Facilitator prepare a summary of the monthly DO activities 
and immunization trends from data 
c. IC and Facilitator prepare a recommendation for office system 
enhancements based on learning  
4. Monthly ACT step - IC presents recommendations to office leadership 
a. IC presents summary, data, and approved recommendations at the 
next staff meeting 
This schedule conforms to the Diffusion of Innovations model by staging communication 
with practice staff over time. Early adopters could emerge as the practice moves through the 
enrollment while the majority would be exposed to training during repeated PDSA cycles. In this 
way, all team members would be allowed to adopt new behaviors at a comfortable pace. Similarly, 
the role-centered meetings were designed to build and strengthen the integrated and compensatory 
implementation drivers of; 1. Competency, 2. Organization and 3. Leadership discussed in 1.1.5.2. 
Sample agendas for the meetings are presented in Appendix B. 
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The first practice was enrolled in the spring of 2015 and was followed by 62 other practices 
as shown in Table 10. The program was terminated in the summer of 2017 in response to shifting 
strategic objectives of the program’s stakeholders. 
Table 10 Enrollment schedule 
Phase Intervention start Location count 
1.0 2015-04-08 14 
2.0 2016-02-28 13 
3.0 2015-08-16 21 
4.0 2016-10-19 13 
5.0 2017-05-06 2 
4.2.2  Analytic Methods 
The effectiveness of the intervention was evaluated using improvements in vaccination 
rates and reductions in missed opportunities to vaccinate. These outcomes were calculated, from 
data files pulled from the health organization’s electronic medical records (EMR). Patient-level 
data was aggregated to practices and outcomes were computed. Outcomes were evaluated using 
an analysis of variance procedure and were considered significant when the alpha level of the F 
statistic was greater than 0.05 and the change in before/after measurements occurred in the 
expected direction. Source code for all data processing steps and analyses is available at 
https://github.com/PittVax/4Pillars_Outcomes including documentation of all software packages 
and versions used. 
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An analyst from the organization generated the data files by searching for patients 60 years 
of age or older who visited any of the practices in the intervention list during the baseline (4/1/2014 
– 3/30/2015) or follow-up (4/1/17-3/30/2018) periods and then retrieving attributes from those 
patient’s records. Each patient was uniquely identified by a record number generated by the 
organization’s de-identification procedure. Birth date was the only demographic information 
provided. 
The available data, which came aggregated to the time period and Location, was parsed 
and carefully examined for anomalies using descriptive statistics and plots then organized into 
‘tidy’ format indexed by Patient ID, Timepoint, Location ID, and Department. Locations could 
include multiple Departments. For example, a location may include Dr. Smith's East Office, Dr. 
Smith's West Office and Dr. Smith's Walk-in-clinics at both offices. Columns included the feature 
values for each uniquely indexed row as follows: 
• the date of the first visit the patient had to any department within the 
Location during the time period, 
• the date of the first visit the patient had to any department within the 
Location during the flu season (August-April) of the time period, 
• the total number of encounters to any Department(s) of the Location during 
the time period, 
• the total number of encounters to any Department(s) of the Location during 
the flu season (August-April) of the time period, 
• the date of the last vaccine administration and 
• an indicator if a vaccine was administered at a visit during the time period. 
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The age-appropriate vaccines recommended to the population during the study were: 
influenza, Pneumo, PCV, Td, Tdap and Zoster. Adult vaccination schedules were unchanged 
throughout the baseline, intervention and follow-up periods; therefore vaccine eligibility was 
calculated identically for each time period using the following recommendations: (See 
compute_vaccine_logic()) 
• Pneumo & PCV should be administered to all patients 65 years or older. 
• Influenza vaccine should be administered to all patients every year. 
• Zoster & Tdap vaccines should be administered to all patients. 
• TD should be administered every 10 years to all patients and can be replaced 
once by a dose of Tdap. 
Indicator variables for vaccine eligibility were added to the data for unvaccinated patients 
meeting the recommendation criteria. Similarly, indicator variables for vaccine administrations 
were tallied from eligible individuals who were vaccinated at a visit or elsewhere during the time 
period. 
These patient-level features were then aggregated to the most granular practice level 
possible – Location. This limitation in the data produced an assumption that all departments within 
a location would have been comparable. Interviews with practice staff and the implementation 
team, suggested that multiple primary care departments within a location would likely be similar, 
however “walk-in clinic” departments may have been qualitatively different than primary care 
departments.  
Figure 11and Figure 12 show two possible Location configurations. For example, one 
could assume that Dr. Li’s East office and Dr. Li’s West office would likely serve similar patient 
populations and have similar staff who would have conducted the intervention in a similar way. 
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However, if Dr. Ismael’s Location included her North office and her walk-in clinic, those 
departments may have had important differences.  
 
Figure 11 Hypothetical location showing a practice with two primary care offices and no walk-in-clinics 
 
Figure 12 Hypothetical location showing a practice with one primary care office and one walk-in-clinic in the 
same building 
Additionally, during the intervention period, the organization underwent a significant 
restructuring where some Locations were closed, consolidated or moved in response to changing 
business conditions in primary care. Consequently, not all Locations had the same departments in 
both the before and after data. To minimize potential confounders, the aggregated data was 
compared by time point and by Location and any anomalous records were either excluded, updated 
or analyzed as described below. 
Departments
Location Dr. Li's Practice
East office 
primary care
West office 
primary care
Departments
Location Dr. Ismael's Practice
North office 
primary care
North office 
Walk-in-clinic
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The function questionable_departments() was used to examine records and adjustments 
were made with update_site_names() and drop_site_records(). Records associated with eight 
different departments changed department ID. Their records were examined with descriptive 
statistics and plots and appeared to be similar to data from other locations. These records were 
recoded so that the Locations could be compared across the time points. Five departments were 
excluded due to missing data from either the baseline or follow-up files. Twelve departments who 
were not enrolled in the intervention were excluded. These records were likely an artifact produced 
by the query used to retrieve the visits associated with specific patients. Excluding these records 
would have no effect on the analysis. Similarly, six “care management” departments were also 
excluded as visits assigned to those codes, would not be expected to assess immunization status 
nor to have the opportunity to administer a vaccine. Finally, three strategies were developed and 
tested to account for Locations which included a walk-in clinic.  
Due to the structure of the available data, excluding visits to the walk-in-clinics could bias 
results for the location. From a provider perspective, walk-in-clinic appointments are focused more 
on emergent conditions and less on preventive care. Though vaccination is rarely contra-indicated 
by the typical conditions addressed in walk-in-clinics, vaccine assessment may be overshadowed 
by more urgent complaints. Similarly, from a patient perspective, vaccination at a walk-in-clinic 
visit may be perceived as too burdensome to consider while injured or ill. Likelihood of 
vaccination may also vary from other departments as not all patients seen in a location's walk-in-
clinic are necessarily primary care patients at the location. That is, patients whose primary care 
provider practices at the location often seek urgent treatment at the location's walk-in-clinic, but 
the reverse may not be true. Three strategies were developed to test the sensitivity of visits coded 
to the walk-in-clinic departments. 
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• Strategy 1 (Filter) included patients seen in the Locations' walk-in-clinics 
in the aggregated location counts. This included visits where assessment of 
vaccination may differ from its priority during a scheduled visit. 
Consequently, if a large proportion of walk-in patients did not also visit the 
location for preventive services the location may have shown more missed 
opportunities. 
• Strategy 2 (Exclude) excluded patients seen in walk-in-clinics from location 
visit counts. This eliminated the count of visits from patients whose medical 
home resides elsewhere but penalizes sites who do prioritize vaccination at 
walk-in clinic appointments. For example, locations who code drop-in 
vaccination clinics as walk-in visits or whose clinical staff do use urgent 
care visits as an opportunity to vaccinate, will not be credited for these 
efforts. 
• Strategy 3 (Drop) excluded all locations with more than a 5% difference 
between patient counts produced by strategy 1 and strategy 2. 
Finally, outcomes were calculated for each Location, vaccine, and time point. The 
vaccination rate was computed as the number of immunized patients divided by the number of 
unique patients. Vaccinations administered during a visit as well as those administered elsewhere, 
were included in these counts. The missed opportunity rate for each vaccine was calculated as the 
ratio of visits by patients eligible and unvaccinated to the total number of visits to the location 
during the time period. 
An analysis of variance (ANOVA) procedure was conducted using the Location-level 
aggregated data for each vaccine for both vaccination rate and missed opportunities. Vaccination 
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outcomes by vaccine were considered significant if the magnitude of the difference between 
baseline and follow-up measurements occurred in the expected direction (increase for vaccination 
rate, decrease for missed opportunities) and if the probability of observing the calculated F statistic 
was <0.05. 
4.3 Results 
4.3.1  Patient descriptors 
As shown in Table 11 and Table 12, 70,503 patients 60 years of age or older, visited an 
intervention location during baseline (19,359 < age 65) and 81,078 during follow-up (21,736 < 
age 65). The intervention was conducted over approximately two years through four major phases 
and one final phase for all remaining location. Assuming that the patient population during the 
intervention was similar to the baseline measurements, each major phase impacted approximately 
15,000 patients and included approximately 15 sites. Proportions of patient ages were similarly 
distributed throughout the phases. Mean number of patients per location was 1,763 (std=1,142). 
 
Table 11 Patient totals by age and time period 
 60-64 65+ Total 
Baseline 19,359 51,144 70,503 
Follow-up 21,736 59,342 81,078 
Total 41,095 110,486 151,581 
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Table 12 Patient totals by age and phase of intervention 
 
60-64 
years 
65+ 
years 
Total Intervention start Location count 
1 4,970 13,101 18,071 4/8/2015 14 
2 4,601 11,851 16,452 2/28/2016 13 
3 5,577 14,139 19,716 8/16/2015 21 
4 3,398 10,122 13,520 10/19/2016 13 
5 813 1,931 2,744 5/6/2017 2 
Total 19,359 51,144 70,503 
  
4.3.2  Adjustments for Locations with a Walk-In-Clinic 
Between the baseline and follow-up data pulls, locations and departments were reorganized 
and many locations added a walk-in-clinic department. Three strategies of modeling the potential 
impact were compared by visually inspecting violin plots and by comparing the results of ANOVA 
analyses using each of the three data sets. There were no substantial differences among the plots 
or statistical tests of the strategies. 
Seven locations were affected by the addition of a walk-in-clinic department. Comparing 
the patient counts produced by the alternative strategies resulted in a five percent difference in four 
locations as shown in Table 13. However, the results of the hypothesis test did not change across 
the three variations of the data. 
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Table 13 Comparison of patient counts using different strategies for walk-in-clinic visits 
Site ID 
Patient count 
with WIC 
(Strategy 1) 
Patient count 
without WIC 
(Strategy 2) 
Percent 
Difference 
> 5% 
Difference 
4 3,016 2,917 1.67% 
 
6 1,693 1,602 2.76% 
 
2 3,595 3,390 2.93% 
 
0 6,950 6,363 4.41% 
 
7 3,449 3,069 5.83% * 
1 2,103 1,362 21.39% * 
5 3,091 1,789 26.68% * 
3 3,247 1,555 35.24% * 
 
Figure 13 through Figure 17 show the similarities among the strategies. Like box and 
whisker plots, violin plots include the most extreme values at either end of the diagram. They also 
convey the shape of the distribution of results through the width and shape of the violin body and 
neck. For example, influenza vaccination rates during baseline appear to be normally distributed 
around 0.55 with some outliers toward 0.30, whereas PCV vaccination rates during baseline are 
asymmetrically skewed towards 0.10.  
 
Figure 13 Walk-in-clinic strategy comparison for influenza outcomes 
96 
 
Figure 14 Walk-in-clinic strategy comparison for PCV outcomes 
 
Figure 15 Walk-in-clinic strategy comparison for TD outcomes 
 
Figure 16 Walk-in-clinic strategy comparison for Tdap outcomes 
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Figure 17 Walk-in-clinic strategy comparison for Zoster outcomes 
After performing these sensitivity tests, Strategy 2 (Exclude) was selected as the most 
representative model of clinical behavior. This excludes patients seen in walk-in-clinics from 
location visit counts. 
4.3.3  Outcomes 
Complete tables of aggregated outcomes are reported in Appendix C. Summaries are 
shown in Table 14 and Table 15. During the baseline period, 70,503 patients logged 246,921 total 
visits to any location with mean patients per location of 1,762.58 (sd=1,142.25) and mean visits 
per location of 6,173.02 (sd=4,309.30). Of those visits, 164,971 occurred during flu vaccination 
season with mean visits per location of 4,124.27 (sd=2923.96). During the follow-up period 81,078 
patients logged 282,279 total visits to any location with mean patients per location of 2,026.95 
(sd=1,271.17) and mean visits per location of 7,056.98 (sd=4,695.81). Of those visits, 191,584 
occurred during flu vaccination season with mean visits per location of 4,789.60 (sd=3,266.89).  
The average number of patients per location who were eligible for each vaccine according 
to CDC recommendations is reported in the column “Vaccine eligible.” At baseline, the vaccines 
with the highest average eligibility were influenza (mean 1395.95, sd 910.70) and PCV (mean 
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1,260.50, sd 823.65). The vaccines with lowest average eligibility were Pneumo (mean 433.65, sd 
320.74) and Td (mean 8.43, sd 10.67). The vaccines for Tdap (mean 1,078.85, sd 722.84) and 
Zoster (mean 1,168.12, sd 769.57) were in the middle of the range of average patients eligible per 
location. The rank order of average eligibility per location was different at Follow up. Influenza 
remained the highest (mean 1,625.72, sd 1,053.50) and Td remained the lowest (mean 30.52, sd 
30.06). The average number of patients per location eligible for Zoster (mean 1,176.00, sd 789.11) 
remained largely unchanged, while PCV (mean 430.45, sd 330.24) and Tdap (mean 900.77, sd 
623.61) both fell and Pneumo (mean 531.45, sd 381.56) rose slightly.  
The average baseline vs follow-up vaccination rates of eligible patients by location were 
computed as: influenza 53.39% vs 31.69%, PCV 13.10% vs 7.83%, Pneumo 6.74% vs 6.85%, Td 
0.06% vs 0.02%, Tdap 7.55% vs 4.84% and Zoster5.62% vs 2.36%. The average numbers of 
vaccines administered during an eligible patient’s visit mirrored the number of eligible patients 
during baseline but not during follow-up. Also, Zoster was rarely administered during a visit 
during either time period despite the large number of eligible patients. 
An analysis of variance procedure was used to identify significant changes in vaccination 
rates and missed opportunities to vaccinate. Results are summarized in Table 16. All outcomes 
except those associated with Pneumo vaccine were significant, however only the reductions in 
missed opportunities to vaccinate with PCV (45.88 percentage point reduction), Tdap (13.39 
percentage point reduction) and Zoster(6.43 percentage point reduction) vaccines were both 
significant at p<0.05 and in the expected direction. All vaccination rates except for Pneumo 
(0.0011 rate increase) were lower during follow-up than during baseline. Influenza rate decreased 
by 0.217, PCV by 0.0527, Td by 0.0004, Tdap by 0.0271 and Zoster by 0.0326. Missed 
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opportunities to vaccinate increased for influenza by 0.2886, Pneumo by 0.0059, and for Td by 
0.01, and decreased for PCV by 0.4588, Tdap by 0.1339 and Zoster by 0.0643. 
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Table 14 Summary of vaccination rates by location by vaccine 
  
Patients Vaccine eligible Immunized Vaccination rate 
  
mean sd mean sd mean sd mean sd 
Baseline Flu 1,762.58 1,142.25 1,395.95 910.70 944.98 648.66 0.5339 0.0834 
PCV 1,762.58 1,142.25 1,260.50 823.65 236.53 190.13 0.1310 0.0569 
Pneumo 1,762.58 1,142.25 433.65 320.74 117.65 91.99 0.0674 0.0240 
Td 1,762.58 1,142.25 8.43 10.67 0.82 1.32 0.0006 0.0011 
Tdap 1,762.58 1,142.25 1,078.85 722.84 140.30 137.23 0.0755 0.0381 
Zoster 1,762.58 1,142.25 1,168.12 769.57 95.40 67.97 0.0562 0.0169 
Follow-up Flu 2,026.95 1,271.17 1,625.72 1,053.50 625.05 466.09 0.3169 0.1038 
PCV 2,026.95 1,271.17 430.45 330.24 155.00 93.93 0.0783 0.0170 
Pneumo 2,026.95 1,271.17 531.45 381.56 138.10 95.16 0.0685 0.0204 
Td 2,026.95 1,271.17 30.52 30.06 0.25 0.49 0.0002 0.0004 
Tdap 2,026.95 1,271.17 900.77 623.61 93.08 59.41 0.0484 0.0180 
Zoster 2,026.95 1,271.17 1,176.00 789.11 45.23 35.29 0.0236 0.0108 
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Table 15 Summary of missed opportunities rates by location by vaccine 
  
Visits during time period Vaccine administered at a visit Vaccine missed opportunities rate 
  
mean sd mean sd mean sd 
Baseline Flu 4,124.27 2,923.96 823.05 569.44 0.3476 0.1112 
PCV 6,173.02 4,309.30 218.82 181.48 0.5843 0.0917 
Pneumo 6,173.02 4,309.30 104.40 83.42 0.1824 0.0743 
Td 6,173.02 4,309.30 0.33 0.86 0.0051 0.0063 
Tdap 6,173.02 4,309.30 124.83 127.82 0.5170 0.1642 
Zoster 6,173.02 4,309.30 54.40 49.14 0.6006 0.1248 
Follow-
up 
Flu 4,789.60 3,266.89 509.20 404.41 0.6362 0.1363 
PCV 7,056.98 4,695.81 142.30 87.74 0.1255 0.0678 
Pneumo 7,056.98 4,695.81 126.70 90.07 0.1883 0.0643 
Td 7,056.98 4,695.81 0.05 0.22 0.0151 0.0108 
Tdap 7,056.98 4,695.81 73.85 48.59 0.3831 0.1370 
Zoster 7,056.98 4,695.81 29.20 27.07 0.5363 0.1195 
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Table 16 Analysis of variance results for vaccination outcomes compared before and after intervention 
  
Baseline Follow-
up 
Sum 
sq 
Df F PR(>F) Significant 
< 0.05 
Significant < 0.05 in 
expected direction 
Vaccination rate Influenza 0.5339 0.3169 0.9418 1 106.2324 0 * 
 
PCV 0.131 0.0783 0.0556 1 31.5145 0 * 
 
Pneumo 0.0674 0.0685 0 1 0.047 0.8289 
  
Td 0.0006 0.0002 0 1 4.3564 0.0401 * 
 
Tdap 0.0755 0.0484 0.0147 1 16.5492 0.0001 * 
 
Zoster 0.0562 0.0236 0.0212 1 105.3741 0 * 
 
Vaccine missed 
opportunities rate 
Influenza 0.3476 0.6362 1.6659 1 107.6812 0 * 
 
PCV 0.5843 0.1255 4.2085 1 647.3124 0 * * 
Pneumo 0.1824 0.1883 0.0007 1 0.1455 0.7039 
  
Td 0.0051 0.0151 0.002 1 26.0067 0 * 
 
Tdap 0.517 0.3831 0.3589 1 15.7038 0.0002 * * 
Zoster 0.6006 0.5363 0.0824 1 5.5223 0.0213 * * 
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4.4 Discussion 
The reduction of missed opportunities to vaccinate with PCV, Tdap and Zoster vaccines 
was statistically significant, however the effectiveness of the intervention remains unclear. Secular 
trends may have confounded the observed results. Data availability and methodologic limitations 
prevented the use of more sophisticated analytic tools.  Future intervention efforts should prioritize 
real-time data availability and tighter integration into existing business operations and workflows. 
The intervention design was a novel use of available resources but was likely less intensive 
than what was provided in prior implementations. Utilizing an educator from industry minimized 
implementation costs but limited the amount of support available to immunization champions at 
each location. Also, using a consultant external to the organization may have reduced the perceived 
importance of the intervention to front-line staff as well as minimized organizational commitment 
to the project. This dynamic was also observed in prior trials where the consultant was part of the 
research team and external to the organization. Future iterations of the program should consider 
using an individual such as an educator or quality assurance team member from within the 
organization as the program facilitator. 
Data availability was another limitation. The organization did not have a clear 
understanding of vaccination outcomes prior to, or during the intervention. The EMR used in the 
organization did not offer the ability to report aggregated measures, so the program participants 
could not automate the motivational strategies from Pillar 4 and did not have the capacity to 
manually track progress. Additionally, the available data may have underreported intervention 
outcomes. With the increase in community vaccination locations such as pharmacies and without 
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mandatory reporting pipelines, it is possible that non-clinical administrations may not be 
consistently entered into the EMR. Because the follow-up data was drawn at differing intervals 
from program completion, performance during and immediately after the intervention may have 
systematically differed from the performance captured in the available data. Though untested, it is 
possible that the observed declines in outcomes were less severe than would have occurred without 
the program, but such an analysis was impossible with the provided data. Future versions of the 
program should not only collect data more proximal to the program, but also return real-time 
progress reports to participants to enhance motivation.  
Finally, the organizational landscape changed dramatically during the intervention period. 
Nationally, insurers, providers and other stakeholders in the health care industry all wrestled with 
policy changes and the shifting paradigm of primary care under the Affordable Care Act as 
evidenced locally by the organization-wide restructuring of departments and business entities. 
Program participants may have been too overwhelmed by disruptions to established routines to 
attend to the quality improvement program. Similarly, research staff have observed firsthand, that 
the EMR has become the primary interface between standards of care and clinical providers. 
Asking providers to switch contexts to an external resource such as a website or to physical job 
aids is a barrier to program fidelity. Consequently, interventions which rely on staff behavior 
change, should be tightly integrated into a stable clinical environment so that a minimum number 
of changes are expected from personnel.  
Despite the ambiguous quantitative results, it is likely that the implementation of the 4 
Pillars™ Practice Transformation Program for Immunization was more beneficial than detrimental 
to the organization and patient population. However, the collaborative design of the intervention 
strategy, limitations in data availability and substantial environmental disruption during the 
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intervention period prevented the replication of results observed in previous clinical trials using 
the program. Future implementations of this and similar programs should prioritize mitigation of 
these issues to achieve maximum impact. 
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5.0 Summary and Conclusions 
Stanley Kubrick and Arthur C. Clarke’s science fiction masterpiece 2001: A Space Odyssey 
(113) chronicles a surprisingly plausible epic that begins with and culminates in the next genesis 
of humankind. Kubrick and Clarke cinematically assert that evolutionary inflection points occur 
with the discovery of new technologies that extend the capabilities of individuals and societies 
which leads to a virtuous cycle of health improvement and morphologic evolution. While their 
vision of 2001 was premature, the storyline is surprisingly plausible. In the fifty years since the 
release of the film, human technologists and explorers have visited the moon, commercialized 
spaceflight and have built primitive artificial intelligence software that may soon control the on-
board systems of our most common terrestrial vehicles.  
As suggested in the iconic sequence of primitive man’s discovery of tools, dramatic 
technological innovations have been enabled by the improvement of humanity’s physical 
conditions. Now motivated by an exponentially growing world population, scientists and engineers 
continue to boost resource production and to learn how to prevent and how to treat the greatest 
threats to life. The traumatic conflict aboard Discovery One between mankind’s hero Dr. David 
Bowman and the personification of technology, HAL-9000, portrays the often-hostile interface 
between scientific advancements and naive humans adapting to new capabilities. Though dystopic, 
it is at this nexus that the greatest evolutionary moments can occur.  
Medical practice and population healthcare embody one of these hostile environments 
where the atomic elements of human beings, scientific innovations and resources collide in an 
ongoing nuclear reaction. When the chain reaction is carefully managed, such as was the case with 
polio eradication, great triumphs are achieved. When the chain reaction becomes unbalanced, it 
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can result in great detriment as was the case with over-prescription of pain relievers and the 
ongoing opioid epidemic. This volatile and highly energetic environment is complex and dynamic. 
It requires safeguards, feedback systems and catalysts analogous to control rods that can govern 
the speed of the reaction. Unfortunately, modern epidemiologists are as far from a real-time 
understanding of the state of population health as 2019 moviegoers are from Kubrick and Clarke’s 
future in 2001. Steps are being taken towards a more flexible health delivery system, however, as 
the same principles of continuous quality improvement championed by the Toyota Method have 
infiltrated the health delivery system. 
5.1 Lessons for Future Implementations of Public Health Interventions Deployed Through 
Primary Care Practices 
In today’s healthcare environment where payors demand efficiency, consumers demand 
convenience and regulators demand quality, medical providers and health administrators are 
struggling to satisfy the expanding needs of all stakeholders. These demanding conditions coupled 
with the relentless advance of treatments, technologies and standards of care challenge the sanity 
of even the most phlegmatic healthcare personnel. Yet, difficulty is no excuse for apathy.  
To codify goals for the health delivery network, standards such as the Medicare Star 
program have been institutionalized for insurers. With strong incentives for compliance, insurers 
are passing relevant expectations on to providers. While setting goals is necessary, goals alone are 
insufficient to achieve changes to long intrenched patterns of behavior. Therefore, quality 
improvement programs such as the 4 Pillars™ Practice Transformation Program for Immunization 
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seek to routinize the path from current behavior to new behaviors better aligned with quality 
standards. 
This transition has proven to be extraordinarily difficult. Even some of the most obvious 
and seemingly simple behaviors take considerable effort to manipulate. Handwashing, for 
example, is an undisputed necessity in modern health care and yet still requires ongoing focus to 
prevent transmission of infections in clinical treatment facilities. As complexity of systems 
increases, so do the challenge to altering that system. Through this struggle, knowledge gaps have 
been filled by the maturing fields of implementation science and quality improvement. Using these 
frameworks, carefully executed clinical trials have demonstrated that clinicians can achieve 
improvements in patient outcomes, but efficiently generalizing this effect to the greater primary 
care health delivery system has yet to be demonstrated reliably in most domains. 
The testing, development and implementation of the 4PPTP have revealed several barriers 
to effective translation and scalability of the program. As is the case with many public health 
initiatives, problems which were addressed by the program at the individual and interpersonal level 
of the social ecological hierarchy are mirrored in the higher, encapsulating levels. Not surprisingly, 
these barriers can be categorized into the same 4 Pillars™ which proved necessary to achieve 
behavior change at the provider and practice level. Moreover, these barriers are likely common 
across many domains of practice so focusing on the solutions to systemic problems should be 
fruitful for outcomes beyond the specific case of vaccination addressed in this project. 
5.1.1.1 Convenience 
Quality improvement interventions must be as simple and time efficient as possible. Staff 
are already burdened with extraordinary responsibility and any changes to routine or the addition 
of new processes represent a cognitive load that is often deferred indefinitely or worse, minimally 
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and incorrectly implemented. It is easy for scientists who may spend years studying a single 
problem, to try to provide as many solutions as possible to affect a change in a clinical outcome. 
However, this shotgun approach is likely to overwhelm staff and to meet organizational resistance.  
At the individual and group level, any intervention strategies that are not virtually 
transparent to staff should be carefully considered and eliminated if possible. If any element of the 
program requires a conscious behavior change, the element should be a necessity to achieving the 
outcome. If a similar outcome can be achieved through the manipulation of any other leverage 
point in the system, that alternate strategy should be selected. Strategies that do require the 
cooperation of team members must be scripted, tested and packaged to gain adoption with the least 
amount of individual effort possible. Support for the behavior change should cascade from the 
most distal inputs through every concentric level of the system surrounding the desired behavior. 
A perfect application of these principles of convenience would make it more difficult for actors to 
avoid the behavior than to execute the behavior. 
Stakeholders at the organizational and institutional level, must be committed to shouldering 
the burden of convenience on behalf of front-line individuals. Implementing a quality 
improvement program requires that administrators, directors, trainers and managers support front-
line staff to achieve the organizational goal. If customization and development of program 
elements is required, those tasks should be completed prior to deploying the program globally with 
representatives from the front-line staff. If an organization is not willing or able to devote 
supportive resources to the effort, implementing the program should be deferred. Considering the 
organization’s placement along the Stages of Change continuum may be helpful to evaluate 
readiness. 
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Intervention consultants and scientists bear the most responsibility for engineering 
convenience. It is not enough to test the components of the intervention. The deployment of the 
intervention must also be tested across a sample of representative organizations. Just as front-line 
staff are overwhelmed with normal duties, so too are non-clinical staff. Organizational effort to 
adopt program elements should be calculated in advance and integrated into whatever workflows 
are necessary to ensure that the element is prepared for system-wide deployment. 
5.1.1.2 Communication 
Change is known to be difficult for organizations and individuals alike. Open 
communication can help to resolve or prevent many problems during program deployment. 
Organizations and teams who cannot demonstrate effective channels of communication, should 
not consider implementing a quality improvement program before remediating this dynamic. Clear 
bi-directional pathways for instructions and feedback must exist or the effort will likely fail. 
Additionally, the organizational culture must include a tolerance for acceptable failures and have 
the capacity to work through setbacks. 
Presenting new policies, procedures and expectations is difficult enough without having to 
also build training and communication systems at the same time. Implementing a quality 
improvement program requires specialized communication tools that may not yet exist within an 
organization. It is likely that an organization will minimally need tools to address staff training, 
compliance monitoring, outcome reporting and coaching. It is helpful, if these tools are commonly 
used throughout the organization and not unique to any one group of individuals. While many 
entities such as accreditation boards, educational institutions and special interest groups offer 
excellent solutions to these needs, they are typically focused on only one individual or one type of 
individual; for example, physicians seeking continuing medical education. This narrow focus is 
111 
prohibitive of organizational adoption. Additionally, external tools are unlikely to offer an 
acceptable level of convenience unless they are used as a part of a more comprehensive solution. 
Finally, communication should be planned as a part of the program deployment. It is typical 
for a new initiative to receive much attention only to be forgotten a few weeks later. Quality 
improvement programs must be discussed periodically to remain salient. Similarly, 
overcommunication can also extinguish interest by becoming part of background corporate noise. 
Scientists and organizational leaders should specify a communication plan that is likely to balance 
the two extremes. Members of the implementation team can quickly check for salience by asking 
participants about the program and may be surprised to find how few team members know about 
the current quality improvement program and goals.  
5.1.1.3 Enhanced Organizational Systems 
This pillar is the most important and the most resource intensive as it is the foundation for 
all program components. By definition, the organizational deployment of any initiative requires 
enhanced systems, otherwise there would not be a need for a quality improvement program. While 
clinicians’ individual judgements and decision making are an important part of medical care, they 
cannot be expected to simply make improvements in patient care without organizational support, 
resources and modifications to existing systems. Quality improvement must be viewed as a team 
sport where every member of the organization contributes to some part of the effort. 
Though the practice of primary care is changing to a more centralized model, the tension 
between clinician autonomy and institutional standardization will remain a challenge and will 
necessitate careful management during implementation. For example, program components must 
be standardized, packaged and convenient but still allow latitude for customizations where 
appropriate. Options should be limited to prevent overwhelming participants, but not so restrictive 
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as to discourage participation. Similarly, systems that are too prescriptive and rigid cannot be used 
for alternative quality improvement programs. In this case, organizations can become cluttered 
with single use tools that cannot be repurposed. During intervention customization, organizations 
should be observant of systemic bottlenecks that can be adjusted to alleviate multiple quality 
endpoints as it is likely that any specific shortcoming is indicative of more systemic problems. 
Where possible, interventions should interface with existing tools and workflows. 
Unfortunately, this is a significant barrier to progress in quality improvement and will remain so 
indefinitely. From the scientist and intervention designer perspective, limited resources prevent 
the development of unique integrations into every organization. From the organization’s 
perspective, adopting new systems and tools is expensive. From the clinician’s perspective, 
anything beyond the EMR window and perhaps email simply doesn’t exist. Consequently, 
delivering the suite of tools required to effectively deploy any quality improvement intervention 
at scale will remain impossible until these dynamics shift. 
5.1.1.4 Motivation 
The ultimate goal of every quality improvement program should be to institutionalize and 
automate systems and to routinize behaviors so that quality outcomes occur independently of 
individual willpower. Maintaining reliance on motivation in the long-term is a poor plan for 
sustainability. Eventually, people get fatigued, new programs become more important and novelty 
wears off. Motivation is useful to defer this inevitable collapse of attention for as long as is 
necessary to generate new routines.  
Notwithstanding the encouragement above to automate as much as possible, one especially 
important insight gathered from prior experience is that participation is a critical part of motivation. 
Most people learn best through active participation in the learning process. The need to standardize 
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processes and procedures needs to be balanced against the human desire to engage with new 
concepts and to work through new challenges. Consequently, effective coaching is an 
indispensable tool during program implementation. Often coaching a participant through a 
challenge will be substantially more motivating than trite awards and platitudes which can 
sometimes produce unintended negative consequences. 
The most significant barrier to effective motivation encountered during this project was a 
lack of real-time data. In general, individuals in healthcare are caring, compassionate and self-
motivated. When presented with an accurate progress report, most participants will dig in and start 
generating new ways to better their team’s score. However, in the absence of periodic updates, 
staff lose interest and can then become defensive and adversarial when reports are finally produced 
after the intervention has concluded. Special care should be taken to provide interim feedback 
about progress towards outcomes so that course corrections can be made before a final outcome is 
calculated. 
5.2 A Final Note About Data and Public Health 
Quality improvement programs are driven by data, yet most personnel in a typical health 
care organization have very little insight into the copious data collected throughout their 
organization. It should be possible for any interested clinician to quickly view both aggregated and 
individual-level statistics for key health outcomes of their patient panel. For example, a clinician 
should be able to check their practice’s performance on any Healthy People goal as easily as 
checking the schedule. Custom reports should be easy to build and accurate.  
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While primary care staff spend an inordinate amount of every encounter performing data 
entry into the EMR, this database is only one of many disparate systems that should be sharing 
information. Primary care physicians have been charged with the responsibility of serving as the 
caretaker of each patient’s medical home, but do not have access to all the information necessary 
to coordinate care. Prescription history is stored in multiple pharmacy databases, vaccinations may 
or may not make it into a state registry, while the records of exercise and heart rate collected by  
watches, bracelets, and dongles and are managed by proprietary services. One has to think that 
bringing this information together would be clinically useful. However, even if the technical 
challenges could be overcome and every bit of health information could be aggregated into a single 
system, the corpus would remain worthless without more sophisticated health modeling and 
simulation capabilities. 
Routine medical services and standards of care are established through rigorous trials, 
clinical experience and epidemiologic study, yet mechanics have more accessible and thorough 
guidance about automotive service schedules and recalls than clinicians have about their patients 
at the point of care. EMR vendors have attempted to solve this disparity with pop-up reminders, 
check boxes, screens of raw data and boilerplate notes populated from a right click menus, but 
most clinicians complain that these endless displays are cumbersome, difficult to navigate and a 
substantial distraction from the human interaction between provider and patient during a clinical 
consultation. Fortunately, software developers, data scientists, industrial designers and multiple 
specialties of engineers are working to solve comparable problems in other domains. These 
solutions from other industries need to be adapted to healthcare. 
Meteorologists have instant access to a global network of sensors, sophisticated weather 
models, data sets and visualization standards that allow any knowledgeable weatherperson to 
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generate a local forecast on command. Automotive engineers can build a virtual engine and 
simulate performance characteristics from their desk. Rocket scientists can experiment with the 
effect of different materials on aerodynamics without needing a wind tunnel, yet physicians don’t 
even have a complete record of their patients’ medications and clinical history. This project 
revealed how common it is to simply accept this reality. Clinicians are resigned to spending more 
time interacting with computers than patients and perceive this effort as malpractice insurance 
rather than scientific data collection. 
Future health technologists must change this paradigm and apply the same methods to 
healthcare that have become commonplace in other fields. The human body is complex, but we 
understand a great deal about how it operates and should be able to generate models and 
simulations that operationalize all our accumulated knowledge of this biologic machine. No single 
physician could ever digest and synthesize all the information that is available about each patient, 
but computers can do so in microseconds.  
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Appendix A Practice Enrollment Materials 
A.1 First Contact Memo 
TO: Practice Staff 
FROM: Organization CEO 
Congratulations! Your practice has been selected to be in the pilot phase of an improvement 
project to increase your vaccination rates within your practice. With our leadership and 
commitment to increase adult immunization rates in your practice, you will make a significant 
difference in patients’ lives.  Your contributions will impact office processes and procedures in 
areas of Patient Access, Patient Notification, Systems Enhancements, and Motivation. 
You will be working with a facilitator from [pharmaceutical company] who will educate 
and provide resources to your practice in the implementation of strategies from the 4 Pillars™ 
Immunization Toolkit. Your colleagues and developers of the Toolkit, Drs. Rick Zimmerman & 
Don Middleton, along with researchers from the Pittsburgh Vaccination Research Group will also 
work with you through this quality improvement initiative. Protocols are being developed to 
enhance the team concept so our staff can assist you and other healthcare workers in closing gaps 
in immunization coverage.  
The goal of the Primary Care Immunization Initiative is to support increasing 
immunization rates in adults. Incorporating adult immunization into the process of vital signs will 
improve the quality of life for our patients and the community in general.  The intention of this 
group is to educate and reinforce the role of the healthcare worker to accomplish this task in the 
physician office. 
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We will need your help to: 
• Identify an “Immunization Champion” (a clinical staff member within your 
practice) who will be supported by the [pharmaceutical company] facilitator and have access to 
the 4 Pillars™ Immunization Toolkit website  
• Provide leadership and motivation within your practice that will allow the program 
to grow and spread  
Our [pharmaceutical company] partners will assist you with the following: 
• Get your Immunization Champion registered and provide resources for the 4 
Pillars™ Immunization Toolkit website so progress of staff education, training, and competencies 
can be tracked 
• Educate and support the Immunization Champion to be the leader in promoting and 
implementing 4 Pillars™ Immunization Toolkit strategies in your office  
• Learn to communicate with and educate patients about the importance of 
immunization  
• Provide feedback to clinical staff in the form of immunization rates 
• Provide resources to help increase your practice’s immunization rates! 
• Thank you in advance for your willingness and support to educate and reinforce the 
role of the healthcare worker in improving patient health through patient centered, quality and 
safety initiatives. 
[pharmaceutical company] Personnel: 
[pharmaceutical company] Vaccine Facilitator:  
[pharmaceutical company] Vaccine Facilitator: [Name] [Phone #] 
[pharmaceutical company] Vaccine Health Science Consultant: [Name] [Phone #] 
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A.2 4 Pillars™ Immunization Toolkit Immunization Improvement Readiness 
Questionnaire 
The following items describe some of the strategies practices might use to maximize adult 
vaccination. Please read each item and check the appropriate column as to whether your practice:  
1) is not currently using; 2) is currently using sometimes; 3) is using routinely; or 4) has not used 
but is interested in trying. 
  My practice is: 
 Strategies Not using 
Using 
sometimes 
Using 
routinely 
Interested 
in trying 
1. Vaccinate/offer vaccines at chronic and 
acute care visits 
□ □ □ □ 
2. Administer two indicated vaccines at the 
same visit (flu and pneumococcal vaccines, 
flu and Tdap vaccines) 
□ □ □ □ 
3. Review patient immunization records during 
vital signs/rooming 
□ □ □ □ 
4. Offer vaccines during regular office hours for 
walk-ins 
□ □ □ □ 
5. Offer other express vaccination services e.g., 
evening and/or weekend flu vaccine only 
sessions 
□ □ □ □ 
6. Set up a dedicated area as a vaccination 
station for walk-ins or nurse vaccination 
visits 
□ □ □ □ 
7. Administer influenza vaccine as early as it is 
available (as early as August) 
□ □ □ □ 
8. Continue to offer flu vaccine until influenza 
season has ended (as late as February) 
□ □ □ □ 
9. On-hold message promotes vaccination 
and/or reminds patients to get vaccinated 
□ □ □ □ 
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  My practice is: 
 Strategies Not using 
Using 
sometimes 
Using 
routinely 
Interested 
in trying 
10. During flu season reception desk staff 
reminds patients that flu vaccine is available 
□ □ □ □ 
11. After-visit summary recommends 
vaccination for next visit if patient is eligible 
and was not vaccinated.   
□ □ □ □ 
12. Generate EMR reports to determine all 
patients who are eligible and not vaccinated 
□ □ □ □ 
13. Actively reach out to patients (call, letter, 
email) who are eligible and not vaccinated 
□ □ □ □ 
14. The current ACIP Adult Immunization 
schedule is posted/visible/easily accessible 
□ □ □ □ 
15. Vaccine educational materials are readily 
available in the waiting room and/or the 
exam rooms 
□ □ □ □ 
16. Vaccination fliers are posted in the waiting 
and/or the exam rooms 
□ □ □ □ 
17. Staff has reviewed specific, tested, culturally 
appropriate statements to encourage 
vaccination 
□ □ □ □ 
18. Staff states that the physicians recommend 
vaccines 
□ □ □ □ 
19. Most staff are vaccinated and expresses 
personal support for vaccination with 
patients 
□ □ □ □ 
20. Staff recommends reliable vaccination 
websites to patients (Families Fighting Flu; 
IAC; PKIDS) 
□ □ □ □ 
21. New hires are in-serviced about vaccination 
priorities   
□ □ □ □ 
22. Clinical staff independently screens patients 
for vaccine eligibility, contraindications and 
precautions 
□ □ □ □ 
23. Clinical staff administers influenza vaccines 
using standing order protocols 
□ □ □ □ 
120 
  My practice is: 
 Strategies Not using 
Using 
sometimes 
Using 
routinely 
Interested 
in trying 
24. Clinical staff administers Tdap vaccines using 
standing order protocols 
□ □ □ □ 
25. Clinical staff administers PPSV vaccines using 
standing order protocols 
□ □ □ □ 
26. Clinical staff administers PCV vaccines using 
standing order protocols 
□ □ □ □ 
27. Clinical staff administers Zoster vaccines 
using standing order protocols 
□ □ □ □ 
28. Staff documents in EMR the reason(s) for 
vaccine refusal 
□ □ □ □ 
29. Staff updates EMR with the vaccines given 
elsewhere (pharmacies) 
□ □ □ □ 
30. Vaccination reports are reviewed and shared 
with staff 
□ □ □ □ 
31. A staff member or provider serves as the 
motivational leader for vaccination activities 
(immunization champion) 
□ □ □ □ 
32. The immunization champion is an individual 
in a leadership role in the practice   
□ □ □ □ 
33. Immunization champion meets regularly 
with other staff members to update them on 
progress and discuss other strategies to 
improve vaccination rates 
□ □ □ □ 
34. Immunization champion updates staff on 
the use and administration of new vaccines, 
new schedules, and new or revised 
recommendations as they become available  
□ □ □ □ 
35. Motivation to improve vaccinations is 
fostered by rewards, competition, 
motivational messaging, etc.   
□ □ □ □ 
36. Strategies to improve vaccination are 
evaluated to determine effectiveness and 
are modified as needed  
□ □ □ □ 
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Appendix B 3 Meeting Kick-Off Series Agendas 
B.1 Practice Leadership Meeting 
Attendees: 
• Office Manager, Lead Physician(s), Facilitator 
Expected duration: 
• 30 mins 
Meeting Objectives:   
• Explain “what” the goal is (data/rates) 
• Explain “why” they were selected  
• Explain “how” they will implement & measure (4Pillars) 
• Define Collaboration with Facilitator 
• Reintroduce Letter from CEO 
• Review IC expectations, punch list & support 
Activities 
• Overview of project timeline & Packet Information 
Mission Statement/Project Goals: 
“The goal of the Immunization Initiative is to support increasing immunization rates in 
adults.  Incorporating adult immunization into the process of vital signs will improve the quality 
of life for our patients and the community in general.  The intention of this group is to educate and 
reinforce the role of the healthcare worker to accomplish this task in the physician office.” 
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Next Steps: 
• Facilitator to check- in 2 days later for post meeting questions 
• Facilitator to pick up skills assessment form within 1-week post meeting 
• Facilitator set next appointment and gain Outlook access to IC calendar 
B.2 Immunization Champion Coaching Meeting 
Attendees: 
• IC, Facilitator 
• Optional but encouraged: Office Manager 
Expected duration: 
• 30 mins 
Meeting Objectives: 
• Review 4 Pillars™ Vaccine Administration Readiness Questionnaire 
• Review office data/stats 
• Introduce 4Pillars™ website & Pillar selections  
• Review how to log on to site & utilization 
• Introduce disease resource handout for patients 
• Review IC expectations 
Next Steps/Follow Up: 
• IC set kick off meeting date with staff 
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• Facilitator to have touch points prior to kick off meeting to assist IC in meeting 
preparation 
• Expectation that Facilitator will be having touch points at least 1x/month with 
office as initiative rolls out; but more or less as needed 
B.3 All Staff Kick Off Meeting 
Attendees: 
• IC, Office Manager, Facilitator, Lead Physician(s), Biller, any staff involved with 
immunization Process 
Expected duration: 
• 1 hr. 
Meeting Objectives:   
• IC /OM to present to staff explanation of initiative  
• Review office immunization rate data 
• Review Skills Assessment Checklist 
• Review 4Pillars™ & selected strategies  
• Explain Facilitator partnership 
• Review office procedure/SOP/Resources 
• Q & A from staff 
• Set next appointment with office 
Next Steps: 
• Obtain agreement from practice & Facilitator on collaboration 
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Appendix C Location Aggregated Data 
    Patients 
    sum mean std min max median 
Time 
period 
Vaccine 
       
Baseline Flu 70,503.00 1,762.58 1,142.25 260.00 5,908.00 1,487.50 
PCV 70,503.00 1,762.58 1,142.25 260.00 5,908.00 1,487.50 
Pneumo 70,503.00 1,762.58 1,142.25 260.00 5,908.00 1,487.50 
Td 70,503.00 1,762.58 1,142.25 260.00 5,908.00 1,487.50 
Tdap 70,503.00 1,762.58 1,142.25 260.00 5,908.00 1,487.50 
Zost 70,503.00 1,762.58 1,142.25 260.00 5,908.00 1,487.50 
Follow-up Flu 81,078.00 2,026.95 1,271.17 338.00 6,363.00 1,740.00 
PCV 81,078.00 2,026.95 1,271.17 338.00 6,363.00 1,740.00 
Pneumo 81,078.00 2,026.95 1,271.17 338.00 6,363.00 1,740.00 
Td 81,078.00 2,026.95 1,271.17 338.00 6,363.00 1,740.00 
Tdap 81,078.00 2,026.95 1,271.17 338.00 6,363.00 1,740.00 
Zost 81,078.00 2,026.95 1,271.17 338.00 6,363.00 1,740.00 
 
    Number of visits during time period 
    sum mean std min max median 
Time 
period 
Vaccine 
       
Baseline Flu 164,971.00 4,124.27 2,923.96 847.00 14,968.00 3,299.00 
PCV 246,921.00 6,173.02 4,309.30 1,284.00 22,059.00 5,038.50 
Pneumo 246,921.00 6,173.02 4,309.30 1,284.00 22,059.00 5,038.50 
Td 246,921.00 6,173.02 4,309.30 1,284.00 22,059.00 5,038.50 
Tdap 246,921.00 6,173.02 4,309.30 1,284.00 22,059.00 5,038.50 
Zost 246,921.00 6,173.02 4,309.30 1,284.00 22,059.00 5,038.50 
Follow-up Flu 191,584.00 4,789.60 3,266.89 935.00 17,223.00 3,908.50 
PCV 282,279.00 7,056.98 4,695.81 1,420.00 24,402.00 5,746.00 
Pneumo 282,279.00 7,056.98 4,695.81 1,420.00 24,402.00 5,746.00 
Td 282,279.00 7,056.98 4,695.81 1,420.00 24,402.00 5,746.00 
Tdap 282,279.00 7,056.98 4,695.81 1,420.00 24,402.00 5,746.00 
Zost 282,279.00 7,056.98 4,695.81 1,420.00 24,402.00 5,746.00 
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    Vaccine eligible 
    sum mean std min max median 
Time 
period 
Vaccine 
       
Baseline Flu 55,838.00 1,395.95 910.70 209.00 4,745.00 1,228.00 
PCV 50,420.00 1,260.50 823.65 151.00 4,132.00 1,068.00 
Pneumo 17,346.00 433.65 320.74 45.00 1,677.00 381.50 
Td 337.00 8.43 10.67 0.00 50.00 5.00 
Tdap 43,154.00 1,078.85 722.84 66.00 3,461.00 1,017.00 
Zost 46,725.00 1,168.12 769.57 173.00 3,717.00 1,078.50 
Follow-up Flu 65,029.00 1,625.72 1,053.50 266.00 5,246.00 1,371.00 
PCV 17,218.00 430.45 330.24 50.00 1,848.00 341.00 
Pneumo 21,258.00 531.45 381.56 66.00 2,027.00 458.50 
Td 1,221.00 30.52 30.06 3.00 133.00 19.00 
Tdap 36,031.00 900.77 623.61 72.00 3,357.00 770.00 
Zost 47,040.00 1,176.00 789.11 182.00 4,258.00 1,012.50 
 
 
    Vaccine administered elsewhere 
    sum mean std min max median 
Time 
period 
Vaccine 
       
Baseline Flu 4,877.00 121.92 87.01 5.00 374.00 107.50 
PCV 708.00 17.70 14.03 0.00 52.00 13.50 
Pneumo 530.00 13.25 10.31 2.00 53.00 11.00 
Td 20.00 0.50 1.01 0.00 4.00 0.00 
Tdap 619.00 15.47 13.66 1.00 59.00 12.00 
Zost 1,640.00 41.00 28.36 7.00 131.00 33.00 
Follow-up Flu 4,634.00 115.85 76.01 15.00 359.00 98.00 
PCV 508.00 12.70 8.42 1.00 33.00 10.50 
Pneumo 456.00 11.40 7.31 1.00 30.00 10.00 
Td 8.00 0.20 0.41 0.00 1.00 0.00 
Tdap 769.00 19.23 18.47 2.00 84.00 14.00 
Zost 641.00 16.02 12.59 1.00 50.00 12.50 
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    Immunized 
    sum mean std min max median 
Time 
period 
Vaccine 
       
Baseline Flu 37,799.00 944.98 648.66 152.00 3,115.00 737.50 
PCV 9,461.00 236.53 190.13 23.00 718.00 157.00 
Pneumo 4,706.00 117.65 91.99 21.00 369.00 90.50 
Td 33.00 0.82 1.32 0.00 5.00 0.00 
Tdap 5,612.00 140.30 137.23 9.00 807.00 118.00 
Zost 3,816.00 95.40 67.97 16.00 362.00 83.50 
Follow-up Flu 25,002.00 625.05 466.09 123.00 2,600.00 499.50 
PCV 6,200.00 155.00 93.93 16.00 388.00 132.50 
Pneumo 5,524.00 138.10 95.16 18.00 448.00 110.50 
Td 10.00 0.25 0.49 0.00 2.00 0.00 
Tdap 3,723.00 93.08 59.41 15.00 219.00 79.00 
Zost 1,809.00 45.23 35.29 5.00 164.00 32.00 
 
    Vaccine missed opportunities rate 
    mean std min max median 
Time 
period 
Vaccine 
      
Baseline Flu 0.3476 0.1112 0.1188 0.6932 0.3424 
PCV 0.5843 0.0917 0.3774 0.7710 0.5908 
Pneumo 0.1824 0.0743 0.0584 0.3976 0.1711 
Td 0.0051 0.0063 0.0000 0.0271 0.0026 
Tdap 0.5170 0.1642 0.1495 0.8015 0.5178 
Zost 0.6006 0.1248 0.3521 0.8446 0.6187 
Follow-up Flu 0.6362 0.1363 0.2305 0.7888 0.6635 
PCV 0.1255 0.0678 0.0424 0.3561 0.1143 
Pneumo 0.1883 0.0643 0.0971 0.3633 0.1830 
Td 0.0151 0.0108 0.0019 0.0494 0.0140 
Tdap 0.3831 0.1370 0.1106 0.7027 0.3762 
Zost 0.5363 0.1195 0.3049 0.7921 0.5399 
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    Vaccination rate 
    mean std min max median 
Time 
period 
Vaccine 
      
Baseline Flu 0.5339 0.0834 0.2662 0.7071 0.5462 
PCV 0.1310 0.0569 0.0325 0.2870 0.1206 
Pneumo 0.0674 0.0240 0.0321 0.1435 0.0620 
Td 0.0006 0.0011 0.0000 0.0044 0.0000 
Tdap 0.0755 0.0381 0.0249 0.2083 0.0653 
Zost 0.0562 0.0169 0.0209 0.0940 0.0554 
Follow-up Flu 0.3169 0.1038 0.2013 0.6432 0.2839 
PCV 0.0783 0.0170 0.0147 0.1150 0.0769 
Pneumo 0.0685 0.0204 0.0206 0.1417 0.0683 
Td 0.0002 0.0004 0.0000 0.0018 0.0000 
Tdap 0.0484 0.0180 0.0161 0.0962 0.0467 
Zost 0.0236 0.0108 0.0037 0.0508 0.0210 
 
128 
Bibliography 
1. Centers for Disease Control and Prevention. Ten Great Public Health Achievements in the 
20th Century online2013 [updated April 26, 2013. Available from: 
http://www.cdc.gov/about/history/tengpha.htm. 
2. Fenner F. Smallpox and its eradication. Geneva: World Health Organization; 1988. xvi, 
1460 p. p. 
3. The Global Polio Eradication Initiative. Polio this week 2016 [Available from: 
http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx. 
4. Centers for Disease C, Prevention. Control of infectious diseases. MMWR Morb Mortal 
Wkly Rep. 1999;48(29):621-9. 
5. Reed C, Kim IK, Singleton JA, Chaves SS, Flannery B, Finelli L, et al. Estimated influenza 
illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season. 
MMWR Morb Mortal Wkly Rep. 2014;63(49):1151-4. 
6. Healthy People 2020. Immunization and Infectious Diseases National Snapshots 
Washington, DC: U.S. Department of Health and Human Services, Office of Disease Prevention 
and Health Promotion; 2016 [updated 07/27/16. Available from: 
https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-
diseases/national-snapshot. 
7. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, State, and 
Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 
2014. MMWR Morb Mortal Wkly Rep. 2015;64(33):889-96. 
8. Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, et al. 
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents 
Aged 13-17 Years--United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784-92. 
9. Appiah GD, Blanton L, D'Mello T, Kniss K, Smith S, Mustaquim D, et al. Influenza 
activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. 
MMWR Morb Mortal Wkly Rep. 2015;64(21):583-90. 
10. Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. 
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. Morbidity 
and mortality weekly report Surveillance summaries (Washington, DC : 2002). 2016;65(1):1-36. 
11. Belongia EA, Naleway AL. Smallpox vaccine: the good, the bad, and the ugly. Clin Med 
Res. 2003;1(2):87-92. 
12. McLeroy KR, Bibeau D, Steckler A, Glanz K. An ecological perspective on health 
promotion programs. Health education quarterly. 1988;15(4):351-77. 
13. Hudsonmh U. Socio-Ecological Model: A framework for community based programs. In: 
Model.png S-E, editor.: Wikipedia; 2014. 
14. Kumar S, Quinn SC, Kim KH, Musa D, Hilyard KM, Freimuth VS. The social ecological 
model as a framework for determinants of 2009 H1N1 influenza vaccine uptake in the United 
States. Health education & behavior : the official publication of the Society for Public Health 
Education. 2012;39(2):229-43. 
129 
15. Centers for Disease C, Prevention. Interim results: state-specific influenza A (H1N1) 2009 
monovalent vaccination coverage - United States, October 2009-January 2010. MMWR Morb 
Mortal Wkly Rep. 2010;59(12):363-8. 
16. Andreasen AR. Marketing social marketing in the social change marketplace. Journal of 
Public Policy & Marketing. 2002;21(1):3-13. 
17. Backer H. Counterpoint: in favor of mandatory influenza vaccine for all health care 
workers. Clinical Infectious Diseases. 2006;42(8):1144-7. 
18. Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with 
immunizations: a decade of professional advancement. Journal of the American Pharmacists 
Association : JAPhA. 2006;46(2):168-79; quiz 79-82. 
19. Diez Roux AV. Complex systems thinking and current impasses in health disparities 
research. Am J Public Health. 2011;101(9):1627-34. 
20. Commission on Social Determinants of Health. Closing the gap in a generation: health 
equity through action on the social determinants of health: final report of the commission on social 
determinants of health. 2008. 
21. Rosenstock IM. The health belief model: Explaining health behavior through expectancies. 
In: Glanz K, Lewis FM, Rimer BK, editors. Health behavior and health education: Theory, 
research, and practice. San Francisco, CA, US: Jossey-Bass; 1990. p. 39-62. 
22. Maddux JE, Rogers RW. Protection motivation and self-efficacy: A revised theory of fear 
appeals and attitude change. Journal of Experimental Social Psychology. 1983;19(5):469-79. 
23. Ajzen I. Theories of Cognitive Self-RegulationThe theory of planned behavior. 
Organizational Behavior and Human Decision Processes. 1991;50(2):179-211. 
24. Gerend MA, Shepherd JE. Predicting human papillomavirus vaccine uptake in young adult 
women: comparing the health belief model and theory of planned behavior. Ann Behav Med. 
2012;44(2):171-80. 
25. Montano DE. Predicting and understanding influenza vaccination behavior. Alternatives 
to the health belief model. Medical care. 1986;24(5):438-53. 
26. Miller JH, Page SE. Complex adaptive systems : an introduction to computational models 
of social life. Princeton, N.J.: Princeton University Press; 2007. xix, 263 p. p. 
27. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, 
systematic review. Prev Med. 2007;45(2-3):107-14. 
28. Charo RA. Politics, parents, and prophylaxis--mandating HPV vaccination in the United 
States. The New England journal of medicine. 2007;356(19):1905-8. 
29. Control CfD, Prevention. Human papillomavirus vaccination coverage among adolescent 
girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR 
Morbidity and mortality weekly report. 2013;62(29):591. 
30. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United 
States. Vaccine. 2010;28(42):6858-67. 
31. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human 
papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA 
pediatrics. 2014;168(1):76-82. 
32. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus 
vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 
2006-2014--United States. MMWR Morbidity and mortality weekly report. 2014;63(29):620-4. 
33. Fisher ES, Shortell SM, Savitz LA. Implementation Science: A Potential Catalyst for 
Delivery System Reform. Jama. 2016;315(4):339-40. 
130 
34. Fixsen DL, Naoom SF, Blase KA, Friedman RM, Wallace F. Implementation Research: A 
Synthesis of the Literature. Tampa, FL: University of South Florida, Institute LdlPFMH; 2005. 
Report No.: FMHI Publication #231. 
35. Bertram RM, Blase KA, Fixsen DL. Improving Programs and Outcomes. Research on 
Social Work Practice. 2014;25(4):477-87. 
36. Fixsen DL, Blase KA, Naoom SF, Wallace F. Core Implementation Components. Research 
on Social Work Practice. 2009;19(5):531-40. 
37. Task Force on Community Preventive Services. Guide to Community Preventive Services 
- Increasing appropriate vaccination. Online [updated April 26, 2016. Available from: 
www.thecommunityguide.org/vaccines/index.html. 
38. Task Force on Community Preventive Services. Vaccine-preventable diseases: improving 
vaccination coverage in children, adolescents, and adults. A report on recommendations from the 
Task Force on Community Preventive Services. MMWR Recomm Rep. 1999;48(RR-8):1-15. 
39. Task Force on Community Preventive Services, Zaza S, Briss P, Harris KW. Vaccine 
preventable diseases.  The Guide to Community Preventive Services: What Works to Promote 
Health? Atlanta GA: Oxford University Press; 2005. p. 223-303. 
40. Allen LJS. Some discrete-time SI, SIR, and SIS epidemic models. Mathematical 
Biosciences. 1994;124(1):83-105. 
41. Zimmerman RK, Nowalk MP. The 4 PillarsTM Practice Transformation Program  
[Available from: http://www.4pillarstoolkit.pitt.edu/. 
42. Nowalk MP, Nolan BA, Nutini J, Ahmed F, Albert SM, Susick M, et al. Success of the 4 
pillars toolkit for influenza and pneumococcal vaccination in adults. Journal for healthcare quality 
: official publication of the National Association for Healthcare Quality. 2014;36(6):5-15. 
43. Zimmerman RK, Nowalk MP. Implementing The 4 Pillars Immunization Toolkit In 
Adolescent Populations: Randomized Controlled Trial. 2014. 
44. Nowalk MP, Zimmerman RK, Lin CJ, Reis EC, Huang HH, Moehling KK, et al. 
Maintenance of Increased Childhood Influenza Vaccination Rates 1 Year After an Intervention in 
Primary Care Practices. Acad Pediatr. 2016;16(1):57-63. 
45. Lin CJ, Nowalk MP, Zimmerman RK, Moehling KK, Conti T, Allred NJ, et al. Reducing 
Racial Disparities in Influenza Vaccination Among Children With Asthma. Journal of pediatric 
health care : official publication of National Association of Pediatric Nurse Associates & 
Practitioners. 2016;30(3):208-15. 
46. Zimmerman RK, Nowalk MP, Lin CJ, Hannibal K, Moehling KK, Huang HH, et al. Cluster 
randomized trial of a toolkit and early vaccine delivery to improve childhood influenza vaccination 
rates in primary care. Vaccine. 2014;32(29):3656-63. 
47. Nowalk MP, Lin CJ, Hannibal K, Reis EC, Gallik G, Moehling KK, et al. Increasing 
childhood influenza vaccination: a cluster randomized trial. Am J Prev Med. 2014;47(4):435-43. 
48. Nowalk MP. Using the 4 Pillars™ Practice Transformation Program to Increase Adult 
Tdap Immunization in a Randomized Controlled Cluster Trial. J Am Geriatr Soc. 2016. 
49. Hawk M. Using a mixed methods approach to examine practice characteristics associated 
with implementation of an adult immunization intervention using the 4 Pillars™ Immunization 
Toolkit. Journal for healthcare quality : official publication of the National Association for 
Healthcare Quality. 2016. 
50. McLaughlin CG, Wyszewianski L. Access to care: remembering old lessons. Health Serv 
Res. 2002;37(6):1441-3. 
131 
51. Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer 
satisfaction. Medical care. 1981;19(2):127-40. 
52. Downs LS, Jr., Scarinci I, Einstein MH, Collins Y, Flowers L. Overcoming the barriers to 
HPV vaccination in high-risk populations in the US. Gynecol Oncol. 2010;117(3):486-90. 
53. Leask J, Kinnersley P, Jackson C, Cheater F, Bedford H, Rowles G. Communicating with 
parents about vaccination: a framework for health professionals. BMC pediatrics. 2012;12(1):154. 
54. Willis N, Hill S, Kaufman J, Lewin S, Kis-Rigo J, De Castro Freire SB, et al. 
"Communicate to vaccinate": the development of a taxonomy of communication interventions to 
improve routine childhood vaccination. BMC Int Health Hum Rights. 2013;13(1):23. 
55. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. 
American journal of health promotion : AJHP. 1997;12(1):38-48. 
56. Centers for Disease Control and Prevention. Immunization Information System (IIS) 
Functional Standards Online [updated December 18, 2012. Available from: 
https://www.cdc.gov/vaccines/programs/iis/func-stds.html. 
57. National Center for Immunization and Respiratory Diseases. Summary of IIS Strategic 
Plan v1.3. Online: Centers for Disease Control and Prevention,; 2013 11/30/2013. 
58. Patwardhan A, Kelleher K, Cunningham D, Spencer C. Improving the influenza 
vaccination rate in patients visiting pediatric rheumatology clinics using automatic best practice 
alert in electronic patient records. Pediatric Rheumatology. 2012;10(Suppl 1):1-2. 
59. Burns IT, Zimmerman RK, Santibanez TA. Effectiveness of chart prompt about 
immunizations in an urban health center. The Journal of family practice. 2002;51(12):1018. 
60. Baron JM, Lewandrowski KB, Kamis IK, Singh B, Belkziz SM, Dighe AS. A novel 
strategy for evaluating the effects of an electronic test ordering alert message: Optimizing cardiac 
marker use. J Pathol Inform. 2012;3:3. 
61. Vashitz G, Meyer J, Parmet Y, Liebermann N, Gilutz H. Factors affecting physicians 
compliance with enrollment suggestions into a clinical reminders intervention. Stud Health 
Technol Inform. 2010;160(Pt 2):796-800. 
62. Payne TH, Hines LE, Chan RC, Hartman S, Kapusnik-Uner J, Russ AL, et al. 
Recommendations to improve the usability of drug-drug interaction clinical decision support 
alerts. J Am Med Inform Assoc. 2015;22(6):1243-50. 
63. Middleton DB, Lin CJ, Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS, et al. 
Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized 
elderly patients. Infect Control Hosp Epidemiol. 2008;29(5):385-94. 
64. Honeycutt AA, Coleman MS, Anderson WL, Wirth KE. Cost-effectiveness of hospital 
vaccination programs in North Carolina. Vaccine. 2007;25(8):1484-96. 
65. Task Force on Community Preventive Services. Guide to Community Preventive Services 
- Vaccination: Standing Orders 2015 [updated 5/26/2016. Available from: 
http://www.thecommunityguide.org/vaccines/standingorders.html. 
66. McKibben LJ, Stange PV, Sneller VP, Strikas RA, Rodewald LE, Advisory Committee on 
Immunization P. Use of standing orders programs to increase adult vaccination rates. MMWR 
Recomm Rep. 2000;49(RR-1):15-6. 
67. Eckrode C, Church N, English WJ, 3rd. Implementation and evaluation of a nursing 
assessment/standing orders-based inpatient pneumococcal vaccination program. Am J Infect 
Control. 2007;35(8):508-15. 
132 
68. Dexter PR, Perkins SM, Maharry KS, Jones K, McDonald CJ. Inpatient computer-based 
standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: 
a randomized trial. Jama. 2004;292(19):2366-71. 
69. Goebel LJ, Neitch SM, Mufson MA. Standing orders in an ambulatory setting increases 
influenza vaccine usage in older people. J Am Geriatr Soc. 2005;53(6):1008-10. 
70. Logue E, Dudley P, Imhoff T, Smucker W, Stapin J, DiSabato J, et al. An opt-out influenza 
vaccination policy improves immunization rates in primary care. J Health Care Poor Underserved. 
2011;22(1):232-42. 
71. Stewart AM, Cox MA, Rosenbaum SJ. THE EPIDEMIOLOGY OF U.S. 
IMMUNIZATION LAW: Translating CDC Immunization Guidelines into Practice: State Laws 
Related to the Use of Standing Orders Covering Immunization Practice. 2005. 
72. Gamble GR, Goldstein AO, Bearman RS. Implementing a standing order immunization 
policy: a minimalist intervention. Journal of the American Board of Family Medicine : JABFM. 
2008;21(1):38-44. 
73. Weiner BJ. A theory of organizational readiness for change. Implement Sci. 2009;4:67. 
74. Bordley WC, Chelminski A, Margolis PA, Kraus R, Szilagyi PG, Vann JJ. The effect of 
audit and feedback on immunization delivery: a systematic review. Am J Prev Med. 
2000;18(4):343-50. 
75. Tomoaia-Cotisel A, Scammon DL, Waitzman NJ, Cronholm PF, Halladay JR, Driscoll DL, 
et al. Context matters: the experience of 14 research teams in systematically reporting contextual 
factors important for practice change. Annals of family medicine. 2013;11 Suppl 1:S115-23. 
76. Mechanic D. Physician discontent: challenges and opportunities. Jama. 2003;290(7):941-
6. 
77. Zimmerman RK, Raviotta JM, Nowalk MP, Moehling KK, Reis EC, Humiston SG, et al. 
Using the 4 Pillars Practice Transformation Program to increase adolescent human papillomavirus, 
meningococcal, tetanus-diphtheria-pertussis and influenza vaccination. Vaccine. 
2017;35(45):6180-6. 
78. Zimmerman RK, Moehling KK, Lin CJ, Zhang S, Raviotta JM, Reis EC, et al. Improving 
adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillars practice 
Transformation Program. Vaccine. 2017;35(1):109-17. 
79. Nowalk MP, Zimmerman RK, Lin CJ, Raviotta JM, Moehling KK, Saul SG, et al. Using 
the 4 Pillars to Increase Vaccination Among High-Risk Adults: Who Benefits?  National Adult 
and Influenza Immunization Summit; 5/17/18; Atlanta, GA2018. 
80. Zimmerman RK, Brown AE, Pavlik VN, Moehling KK, Raviotta JM, Lin CJ, et al. Using 
the 4 Pillars Practice Transformation Program to Increase Pneumococcal Immunizations for Older 
Adults: A Cluster-Randomized Trial. J Am Geriatr Soc. 2017;65(1):114-22. 
81. Nowalk MP, Zimmerman RK, Lin CJ, Raymund M, Tabbarah M, Wilson SA, et al. Raising 
adult vaccination rates over 4 years among racially diverse patients at inner-city health centers. J 
Am Geriatr Soc. 2008;56(7):1177-82. 
82. Oldenburg B, Parcel S. Diffusion of Innovations. In: Glanz K, Rimer B, Lewis F, editors. 
Health Behavior and Health Education. 3rd ed. San Francisco: John Wiley and Sons, Inc; 2002. p. 
312-34. 
83. Lin CJ, Nowalk MP, Pavlik VN, Brown AE, Zhang S, Raviotta JM, et al. Using the 4 pillars 
practice transformation program to increase adult influenza vaccination and reduce missed 
opportunities in a randomized cluster trial. BMC infectious diseases. 2016;16(1):623. 
133 
84. Smith KJ, Nowalk MP, Lin CJ, Zimmerman RK. Cost effectiveness of a practice-based 
intervention to improve vaccination rates in adults less than 65-years-old. Hum Vaccin 
Immunother. 2017;13(10):2207-12. 
85. Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ. Cost-Effectiveness of the 4 Pillars 
Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. J Am 
Geriatr Soc. 2017;65(4):763-8. 
86. Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ. Cost-Effectiveness of the 4 Pillars 
Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. J Am 
Geriatr Soc. 2016. 
87. Community Preventive Services Task Force. The Community Guide 2011 [Available 
from: www.thecommunityguide.org. 
88. American Board of Family Medicine. ABFM | Performance Improvement 2018 [Available 
from: https://www.theabfm.org/moc/pi.aspx. 
89. Advisory Committee on Immunization Practice. Recommended Vaccines for Adults | CDC 
2018 [updated 2018-01-25T06:40:51Z. Available from: https://www.cdc.gov/vaccines/adults/rec-
vac/index.html. 
90. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR, Centers for Disease C, Prevention. 
Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 
2014;63(33):729-31. 
91. Centers for Medicare & Medicaid Services. Physician Fee Schedule Search 7500 Security 
Boulevard, Baltimore, MD 21244: Centers for Medicare & Medicaid Services; 2014 [Available 
from: http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. 
92. The Centers For Disease Control and Prevention. Vaccine Price List 2014 [Available from: 
http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. 
93. Prelog M. Differential approaches for vaccination from childhood to old age. Gerontology. 
2013;59(3):230-9. 
94. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling 
of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J 
Prev Med. 2013;44(4):373-81. 
95. U.S. Census Bureau PD. Annual Estimates of the Resident Population by Single Year of 
Age and Sex for the United States, States, and Puerto Rico Commonwealth: April 1, 2010 to July 
1, 2016 2017 [Available from: 
https://factfinder.census.gov/bkmk/table/1.0/en/PEP/2016/PEPSYASEX. 
96. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. 
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness 
Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. Jama. 2016;316(10):1093-
103. 
97. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes 
zoster and postherpetic neuralgia in older adults. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America. 2007;44(10):1280-8. 
98. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and 
economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged >/=50 years. 
Vaccine. 2012;30(36):5437-44. 
99. Prevention CfDCa. Archived CDC Vaccine Price List as of November 5, 2015 2015 
[Available from: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-
management/price-list/2015/2015-11-05.html. 
134 
100. Gnann JW, Jr., Whitley RJ. Clinical practice. Herpes zoster. The New England journal of 
medicine. 2002;347(5):340-6. 
101. Centers for Disease Control and Prevention NCfHS. Underlying Cause of Death 1999-
2016 on CDC WONDER Online Database 2005 [updated December, 2017. Data are from the 
Multiple Cause of Death Files, 1999-2016, as compiled from data provided by the 57 vital statistics 
jurisdictions through the Vital Statistics Cooperative Program]. Available from: 
http://wonder.cdc.gov/ucd-icd10.html. 
102. Le P, Rothberg MB. Cost Effectiveness of a Shingles Vaccine Booster for Currently 
Vaccinated Adults in the U.S. Am J Prev Med. 2017;53(6):829-36. 
103. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, 
Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden 
and costs. Vaccine. 2007;25(27):5086-96. 
104. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine 
to prevent herpes zoster and postherpetic neuralgia in older adults. The New England journal of 
medicine. 2005;352(22):2271-84. 
105. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. 
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. The New England 
journal of medicine. 2015;372(12):1114-25. 
106. Koepke R, Eickhoff JC, Ayele RA, Petit AB, Schauer SL, Hopfensperger DJ, et al. 
Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for 
preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap 
brand. The Journal of infectious diseases. 2014;210(6):942-53. 
107. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect 
of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease 
in children and adults in the USA: analysis of multisite, population-based surveillance. The Lancet 
Infectious Diseases. 2015;15(3):301-9. 
108. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-
effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with 
pneumococcal polysaccharide vaccine. Jama. 2012;307(8):804-12. 
109. Flatt A, Breuer J. Varicella vaccines. Br Med Bull. 2012;103(1):115-27. 
110. Centers for Disease Control and Prevention NCfHS. Underlying Cause of Death 1999-
2016 on CDC WONDER Online Database 2015 [updated December, 2017. Data are from the 
Multiple Cause of Death Files, 1999-2016, as compiled from data provided by the 57 vital statistics 
jurisdictions through the Vital Statistics Cooperative Program]. Available from: 
http://wonder.cdc.gov/ucd-icd10.html. 
111. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-
associated hospitalizations in the United States. Jama. 2004;292(11):1333-40. 
112. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the 
Panel on Cost-effectiveness in Health and Medicine. Jama. 1996;276(15):1253-8. 
113. Kubrick S. 2001: A Space Odyssey. Metro-Goldwyn-Mayer, Inc.; 1968. 
 
